Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Laboratory tests for evaluating the individual's clotting mechanism.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Absence or reduced levels of PROTHROMBIN in the blood.
A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)
Agents that prevent clotting.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
Substances found in many plants, containing the 4-hydroxycoumarin radical. They interfere with vitamin K and the blood clotting mechanism, are tightly protein-bound, inhibit mitochondrial and microsomal enzymes, and are used as oral anticoagulants.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Method of tissue preparation in which the tissue specimen is frozen and then dehydrated at low temperature in a high vacuum. This method is also used for dehydrating pharmaceutical and food products.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Activated form of factor V. It is an essential cofactor for the activation of prothrombin catalyzed by factor Xa.
A bile pigment that is a degradation product of HEME.
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Bleeding or escape of blood from a vessel.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Laboratory and other services provided to patients at the bedside. These include diagnostic and laboratory testing using automated information entry.
Agents that cause clotting.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
Formation and development of a thrombus or blood clot in the blood vessel.
The natural enzymatic dissolution of FIBRIN.
Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.
Found in various tissues, particularly in four blood-clotting proteins including prothrombin, in kidney protein, in bone protein, and in the protein present in various ectopic calcifications.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
Determination, by measurement or comparison with a standard, of the correct value of each scale reading on a meter or other measuring instrument; or determination of the settings of a control device that correspond to particular values of voltage, current, frequency or other output.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
Compounds used in food or in food preparation to replace dietary fats. They may be carbohydrate-, protein-, or fat-based. Fat substitutes are usually lower in calories but provide the same texture as fats.
Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid.
Pathological processes of the LIVER.
Control of bleeding during or after surgery.
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
The giving of drugs, chemicals, or other substances by mouth.
The formation or presence of a blood clot (THROMBUS) within a vein.
Substances used to destroy or inhibit the action of rats, mice, or other rodents.
Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens).
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
The transference of a part of or an entire liver from one human or animal to another.
Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of C(l) on C(4).
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
An absence or reduced level of blood coagulation factor XII. It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time.
A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.
Tests used in the analysis of the hemic system.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Pipecolic acids are cyclic amino acids, specifically a derivative of L-lysine, that can function as an indicator of certain metabolic disorders such as lysinuric protein intolerance and maple syrup urine disease.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
Triple-looped protein domains linked by disulfide bonds. These common structural domains, so-named for their resemblance to Danish pastries known as kringlers, play a role in binding membranes, proteins, and phospholipids as well as in regulating proteolysis. Kringles are also present in coagulation-related and fibrinolytic proteins and other plasma proteinases.
The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.
Hemorrhage following any surgical procedure. It may be immediate or delayed and is not restricted to the surgical wound.
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Techniques for controlling bleeding.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
Elements of limited time intervals, contributing to particular results or situations.
Physiologically inactive substances that can be converted to active enzymes.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
The rate dynamics in chemical or physical systems.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
Loss of blood during a surgical procedure.
A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy.
A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed)
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499)
Excision of all or part of the liver. (Dorland, 28th ed)
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).
A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.

Values of three coagulation screening tests of precolostral calves. (1/733)

Prothrombin times, partial thromboplastin times and platelet counts were performed to determine normal values and to screen for coagulation defects of precolostral calves. The precolostral calves were in two groups: one group of a few calves was tested two years before the second larger group. The results for both groups were similar. The tests were performed on postcolostral calves and on mature cows to compare their values with those of precolostral calves. The mean values of prothrombin times and partial thromboplastin times of precolostral calves in the first group were 18.8 seconds and 54.8 seconds respectively. The mean values of prothrombin times and partial thromboplastin times of precolostral calves in the second group were 18.8 seconds and 50.8 seconds respectively. The mean platelet count was 422,400/cmm for the first group and 482,800/cmm for the second group.  (+info)

Factor VII as a marker of hepatocellular synthetic function in liver disease. (2/733)

Factor VII levels have been measured in 100 patients with liver disease following parenteral vitamin K1 therapy. There was good agreement between specific factor VII measurements and the one-stage prothrombin time apart from six patients with compensated cirrhosis in whom the prothrombin time was prolonged despite the presence of normal factor VII levels. A mean activity of 58% was found in patients with cirrhosis. Cirrhotic patients with features of hepatic decompensation had a significantly lower mean level of activity (40%) than the "contrast" patients with surgical obstruction of the major bile ducts (93%). Patients with chronic active liver disease had moderate depression of factor VII levels and those with non-cirrhotic liver damage had mean activities similar to the contrast group. Factor VII levels could not be correlated with BSP retention but there was a correlation with serum albumin concentration. It is concluded that the prothrombin time using Quick test with a standardized thromboplastin showing good sensitivity to factor VII, eg, the Manchester reagent (BCT), provides a reliable index of coagulability in chronic liver disease, and specific factor VII assays are not indicated.  (+info)

Medical liability risk avoidance: a case for adopting the International Normalized Ratio (INR) system. (3/733)

Since bleeding is a common adverse effect associated with the oral anticoagulant warfarin, maximizing the therapeutic potential of this drug requires close laboratory monitoring. The International Normalized Ratio (INR) is a system that has been developed to improve and standardize the assessment of the intensity of oral anticoagulation therapy. Clinical information and medicolegal arguments supporting the adoption of this system are reviewed. The potential for improvement in patient outcomes and minimization of medical liability favors the adoption of the INR system.  (+info)

Effect of liver disease and transplantation on urea synthesis in humans: relationship to acid-base status. (4/733)

It has been suggested that hepatic urea synthesis, which consumes HCO-3, plays an important role in acid-base homeostasis. This study measured urea synthesis rate (Ra urea) directly to assess its role in determining the acid-base status in patients with end-stage cirrhosis and after orthotopic liver transplantation (OLT). Cirrhotic patients were studied before surgery (n = 7) and on the second postoperative day (n = 11), using a 5-h primed-constant infusion of [15N2]urea. Six healthy volunteers served as controls. Ra urea was 5.05 +/- 0.40 (SE) and 3.11 +/- 0.51 micromol. kg-1. min-1, respectively, in controls and patients with cirrhosis (P < 0. 05). Arterial base excess was 0.6 +/- 0.3 meq/l in controls and -1.1 +/- 1.3 meq/l in cirrhotic patients (not different). After OLT, Ra urea was 15.05 +/- 1.73 micromol. kg-1. min-1, which accompanied an arterial base excess of 7.0 +/- 0.3 meq/l (P < 0.001). We conclude that impaired Ra urea in cirrhotic patients does not produce metabolic alkalosis. Concurrent postoperative metabolic alkalosis and increased Ra urea indicate that the alkalosis is not caused by impaired Ra urea. It is consistent with, but does not prove, the concept that the graft liver responds to metabolic alkalosis by augmenting Ra urea, thus increasing HCO-3 consumption and moderating the severity of metabolic alkalosis produced elsewhere.  (+info)

Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. (5/733)

The main cause of acute coronary syndrome may be recurrent thrombosis, which is initiated by the activation of the extrinsic coagulation pathway. Tissue factor (TF) pathway inhibitor (TFPI) efficiently inhibits an early step in this pathway by the formation of a complex with factor VIIa, TF, and factor Xa. We determined whether local TFPI gene transfer can inhibit thrombosis in an injured artery without inducing systemic side effects. Balloon-injured rabbit carotid arteries were infected with an adenoviral vector that expressed either human TFPI (AdCATFPI) or bacterial beta-galactosidase (AdCALacZ). Two to 6 days after gene transfer, thrombosis was induced by the production of constant stenosis of the artery, and blood flow was measured continuously with an electromagnetic flow probe. A cyclic flow variation, which is thought to reflect the recurrent formation and dislodgment of mural thrombi, was observed in all AdCALacZ-infected arteries as well as in saline-infused arteries. In contrast, no cyclic flow variation was detectable in AdCATFPI-transfected arteries, even in the presence of epinephrine (1 microg. kg-1. min-1 infusion). Prothrombin time, activated partial thromboplastin time, and the ex vivo platelet aggregation induced by either adenosine diphosphate or collagen were unaltered in AdCATFPI-infected rabbits. We found that in vivo TFPI gene transfer into an injured artery completely inhibits the recurrent thrombosis induced by shear stress even in the presence of catecholamine, without affecting systemic coagulation status. Adenovirus-mediated local expression of TFPI may have the potential for the treatment of human thrombosis.  (+info)

Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. (6/733)

A murine antihuman factor IX monoclonal antibody (BC2) has been generated and evaluated for its capacity to prolong the activated partial thromboplastin time (aPTT) in vitro and ex vivo and to prevent arterial thrombosis in a rat model in vivo. BC2 extended aPTT to a maximum of 60 to 80 seconds at 100 to 1000 nmol/L in vitro (rat and human plasma, respectively) and ex vivo (rat) after dosing of rats up to 6 mg/kg in vivo. BC2, administered as bolus (1 to 6 mg/kg) followed by infusion (0.3 to 2 mg x kg(-1) x h(-1)), dose-dependently prevented thrombosis of an injured rat carotid artery (FeCl(3)-patch model), increased time to artery occlusion, and reduced incidence of vessel occlusion. BC2 efficacy in preventing arterial thrombosis exceeded that of heparin (bolus 15 to 120 U/kg followed by infusion 0.5 to 4.0 U x kg(-1) x min(-1)), whereas the latter rendered the blood incoagulable (aPTT>1000 seconds). BC2 demonstrated complete antithrombotic efficacy also as a single bolus given either as prevessel or postvessel injury as evidenced by reduction of thrombus mass (from 4.18+/-0.49 to 1.80 +/-0.3 mg, P<0.001), increasing vessel patency time (from 14.9+/-0.9 minutes to 58.3+/-1.7 minutes, P<0.001) and decreasing incidence of vessel occlusion from 100% to 0% in vehicle- versus BC2-treated rats, respectively. BC2 (3 mg/kg, IV) administered in a single bolus resulted in 50% reduction in thrombus mass (P<0.01), extended vessel patency time (P<0.001), extended aPTT only 4-fold, and had no effect on blood loss via a tail surgical wound; heparin, at doses that reduced thrombus mass to a similar extent, extended aPTT beyond 1000 seconds (over 500-fold) and increased blood loss from 1.8+/-0.7 to 3.3 +/-0.6 mL (P<0.001). These data suggest that BC2 may provide enhanced therapeutic efficacy in humans at lesser interference with blood hemostasis than heparin.  (+info)

An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. (7/733)

OBJECTIVE: To test the hypothesis that some lupus anticoagulants are antiprothrombin antibodies, and that such antibodies enhance prothrombin binding to endothelial cells (EC) and thus promote clotting on the cell surface. METHODS: We generated a monoclonal antiprothrombin antibody (designated IS6) from a patient with primary antiphospholipid syndrome (APS). The antibody was analyzed for its binding properties, lupus anticoagulant activity, and pathophysiologic activity, using an EC-based plasma coagulation assay. RESULTS: IS6 is the first patient-derived monoclonal IgG antiprothrombin antibody. It bound to prothrombin with low affinity, reacted with 3 phospholipids (cardiolipin, phosphatidylethanolamine, and phosphatidylserine), and showed lupus anticoagulant activity. Moreover, IS6 enhanced the binding of prothrombin to damaged EC and shortened the EC-based plasma coagulation times. CONCLUSION: These findings suggest that IS6 may promote coagulation in areas of damaged EC in the host, and thus contribute to thrombosis in patients with APS.  (+info)

Effect of maternal anticonvulsant treatment on neonatal blood coagulation. (8/733)

AIMS: To investigate the impact of maternal anticonvulsant use on the ability of cord blood to coagulate. METHODS: Cord blood prothrombin times were measured, over 15 years in a consecutive series of 137 term babies born to women taking phenobarbitone, phenytoin, and/or carbamazepine while pregnant. The response to parenteral vitamin K was measured in 83 neonates. RESULTS: Only 14 of the 105 babies born to the mothers who had therapeutic anticonvulsant blood concentrations at birth had a prolonged prothrombin time (outside the 95% reference range). None had an overt bleeding tendency. The abnormality was corrected within 2 hours by 1 mg of parenteral vitamin K, but rapid intravenous prophylaxis produced complications in three infants. CONCLUSIONS: A policy of giving vitamin K throughout the last third of pregnancy to all women being treated with anticonvulsants, as recently recommended, is not justified by the available evidence. The belief that there is a distinct, early form of neonatal vitamin K deficiency that is different from, and more dangerous than, the classic form of the disease, is not supported by a review of the published evidence.  (+info)

Prothrombin time (PT) is a medical laboratory test that measures the time it takes for blood to clot. It's often used to evaluate the functioning of the extrinsic and common pathways of the coagulation system, which is responsible for blood clotting. Specifically, PT measures how long it takes for prothrombin (a protein produced by the liver) to be converted into thrombin, an enzyme that converts fibrinogen into fibrin and helps form a clot.

Prolonged PT may indicate a bleeding disorder or a deficiency in coagulation factors, such as vitamin K deficiency or the use of anticoagulant medications like warfarin. It's important to note that PT is often reported with an international normalized ratio (INR), which allows for standardization and comparison of results across different laboratories and reagent types.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Partial Thromboplastin Time (PTT) is a medical laboratory test that measures the time it takes for blood to clot. It's more specifically a measure of the intrinsic and common pathways of the coagulation cascade, which are the series of chemical reactions that lead to the formation of a clot.

The test involves adding a partial thromboplastin reagent (an activator of the intrinsic pathway) and calcium to plasma, and then measuring the time it takes for a fibrin clot to form. This is compared to a control sample, and the ratio of the two times is calculated.

The PTT test is often used to help diagnose bleeding disorders or abnormal blood clotting, such as hemophilia or disseminated intravascular coagulation (DIC). It can also be used to monitor the effectiveness of anticoagulant therapy, such as heparin. Prolonged PTT results may indicate a bleeding disorder or an increased risk of bleeding, while shortened PTT results may indicate a hypercoagulable state and an increased risk of thrombosis.

Blood coagulation tests, also known as coagulation studies or clotting tests, are a series of medical tests used to evaluate the blood's ability to clot. These tests measure the functioning of various clotting factors and regulatory proteins involved in the coagulation cascade, which is a complex process that leads to the formation of a blood clot to prevent excessive bleeding.

The most commonly performed coagulation tests include:

1. Prothrombin Time (PT): Measures the time it takes for a sample of plasma to clot after the addition of calcium and tissue factor, which activates the extrinsic pathway of coagulation. The PT is reported in seconds and can be converted to an International Normalized Ratio (INR) to monitor anticoagulant therapy.
2. Activated Partial Thromboplastin Time (aPTT): Measures the time it takes for a sample of plasma to clot after the addition of calcium, phospholipid, and a contact activator, which activates the intrinsic pathway of coagulation. The aPTT is reported in seconds and is used to monitor heparin therapy.
3. Thrombin Time (TT): Measures the time it takes for a sample of plasma to clot after the addition of thrombin, which directly converts fibrinogen to fibrin. The TT is reported in seconds and can be used to detect the presence of fibrin degradation products or abnormalities in fibrinogen function.
4. Fibrinogen Level: Measures the amount of fibrinogen, a protein involved in clot formation, present in the blood. The level is reported in grams per liter (g/L) and can be used to assess bleeding risk or the effectiveness of fibrinogen replacement therapy.
5. D-dimer Level: Measures the amount of D-dimer, a protein fragment produced during the breakdown of a blood clot, present in the blood. The level is reported in micrograms per milliliter (µg/mL) and can be used to diagnose or exclude venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

These tests are important for the diagnosis, management, and monitoring of various bleeding and clotting disorders. They can help identify the underlying cause of abnormal bleeding or clotting, guide appropriate treatment decisions, and monitor the effectiveness of therapy. It is essential to interpret these test results in conjunction with a patient's clinical presentation and medical history.

Blood coagulation disorders, also known as bleeding disorders or clotting disorders, refer to a group of medical conditions that affect the body's ability to form blood clots properly. Normally, when a blood vessel is injured, the body's coagulation system works to form a clot to stop the bleeding and promote healing.

In blood coagulation disorders, there can be either an increased tendency to bleed due to problems with the formation of clots (hemorrhagic disorder), or an increased tendency for clots to form inappropriately even without injury, leading to blockages in the blood vessels (thrombotic disorder).

Examples of hemorrhagic disorders include:

1. Hemophilia - a genetic disorder that affects the ability to form clots due to deficiencies in clotting factors VIII or IX.
2. Von Willebrand disease - another genetic disorder caused by a deficiency or abnormality of the von Willebrand factor, which helps platelets stick together to form a clot.
3. Liver diseases - can lead to decreased production of coagulation factors, increasing the risk of bleeding.
4. Disseminated intravascular coagulation (DIC) - a serious condition where clotting and bleeding occur simultaneously due to widespread activation of the coagulation system.

Examples of thrombotic disorders include:

1. Factor V Leiden mutation - a genetic disorder that increases the risk of inappropriate blood clot formation.
2. Antithrombin III deficiency - a genetic disorder that impairs the body's ability to break down clots, increasing the risk of thrombosis.
3. Protein C or S deficiencies - genetic disorders that lead to an increased risk of thrombosis due to impaired regulation of the coagulation system.
4. Antiphospholipid syndrome (APS) - an autoimmune disorder where the body produces antibodies against its own clotting factors, increasing the risk of thrombosis.

Treatment for blood coagulation disorders depends on the specific diagnosis and may include medications to manage bleeding or prevent clots, as well as lifestyle changes and monitoring to reduce the risk of complications.

The International Normalized Ratio (INR) is a standardized measurement of the prothrombin time (PT), which is the time it takes for blood to clot. The INR is used to monitor and regulate the effects of anticoagulant medications, such as warfarin, that affect the blood's ability to clot.

The INR is calculated by dividing the patient's PT by a control value (the PT of normal, healthy blood), raised to the power of a sensitivity factor called the International Sensitivity Index (ISI). The ISI is specific to the thromboplastin reagent used in the PT assay.

The INR provides a consistent and comparable way to monitor anticoagulation therapy across different laboratories, regardless of the thromboplastin reagent used. This helps ensure that patients receive appropriate doses of anticoagulant medications and reduces the risk of bleeding or clotting complications.

In general, an INR range of 2.0 to 3.0 is recommended for most people taking anticoagulants for conditions such as atrial fibrillation, deep vein thrombosis, or pulmonary embolism. However, the target INR range may vary depending on individual patient factors and medical indications.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Hypoprothrombinemia is a medical condition characterized by a decreased level of prothrombin (coagulation factor II) in the blood, which can lead to an increased bleeding tendency. Prothrombin is a protein involved in the coagulation cascade that helps to form blood clots and stop bleeding.

Hypoprothrombinemia can be caused by various factors, including vitamin K deficiency, liver disease, inherited or acquired disorders of prothrombin synthesis, or the use of certain medications such as warfarin. Symptoms may include easy bruising, prolonged bleeding from cuts or injuries, nosebleeds, and in severe cases, internal bleeding. Treatment typically involves addressing the underlying cause and may include vitamin K supplementation, fresh frozen plasma transfusions, or other specific therapies depending on the etiology of the condition.

Vitamin K deficiency is a condition that occurs when the body lacks adequate amounts of Vitamin K, a fat-soluble vitamin essential for blood clotting and bone metabolism. This can lead to an increased risk of excessive bleeding (hemorrhage) and calcification of tissues.

Vitamin K is required for the activation of several proteins involved in blood clotting, known as coagulation factors II, VII, IX, and X. A deficiency in Vitamin K can result in these factors remaining in their inactive forms, leading to impaired blood clotting and an increased risk of bleeding.

Vitamin K deficiency can occur due to several reasons, including malnutrition, malabsorption disorders (such as cystic fibrosis or celiac disease), liver diseases, use of certain medications (such as antibiotics or anticoagulants), and prolonged use of warfarin therapy.

In newborns, Vitamin K deficiency can lead to a serious bleeding disorder known as hemorrhagic disease of the newborn. This is because newborns have low levels of Vitamin K at birth, and their gut bacteria, which are responsible for producing Vitamin K, are not yet fully developed. Therefore, it is recommended that newborns receive a dose of Vitamin K within the first few days of life to prevent this condition.

Symptoms of Vitamin K deficiency can include easy bruising, nosebleeds, bleeding gums, blood in urine or stools, and excessive menstrual bleeding. In severe cases, it can lead to life-threatening hemorrhage. Treatment typically involves administering Vitamin K supplements or injections to replenish the body's levels of this essential nutrient.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Warfarin is a anticoagulant medication that works by inhibiting the vitamin K-dependent activation of several coagulation factors (factors II, VII, IX, and X). This results in prolonged clotting times and reduced thrombus formation. It is commonly used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Warfarin is also known by its brand names Coumadin and Jantoven.

It's important to note that warfarin has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic one is small. Therefore, it requires careful monitoring of the patient's coagulation status through regular blood tests (INR) to ensure that the dosage is appropriate and to minimize the risk of bleeding complications.

Blood coagulation factors, also known as clotting factors, are a group of proteins that play a crucial role in the blood coagulation process. They are essential for maintaining hemostasis, which is the body's ability to stop bleeding after injury.

There are 13 known blood coagulation factors, and they are designated by Roman numerals I through XIII. These factors are produced in the liver and are normally present in an inactive form in the blood. When there is an injury to a blood vessel, the coagulation process is initiated, leading to the activation of these factors in a specific order.

The coagulation cascade involves two pathways: the intrinsic and extrinsic pathways. The intrinsic pathway is activated when there is damage to the blood vessel itself, while the extrinsic pathway is activated by tissue factor released from damaged tissues. Both pathways converge at the common pathway, leading to the formation of a fibrin clot.

Blood coagulation factors work together in a complex series of reactions that involve activation, binding, and proteolysis. When one factor is activated, it activates the next factor in the cascade, and so on. This process continues until a stable fibrin clot is formed.

Deficiencies or abnormalities in blood coagulation factors can lead to bleeding disorders such as hemophilia or thrombosis. Hemophilia is a genetic disorder that affects one or more of the coagulation factors, leading to excessive bleeding and difficulty forming clots. Thrombosis, on the other hand, occurs when there is an abnormal formation of blood clots in the blood vessels, which can lead to serious complications such as stroke or pulmonary embolism.

Vitamin K is a fat-soluble vitamin that plays a crucial role in blood clotting and bone metabolism. It is essential for the production of several proteins involved in blood clotting, including factor II (prothrombin), factor VII, factor IX, and factor X. Additionally, Vitamin K is necessary for the synthesis of osteocalcin, a protein that contributes to bone health by regulating the deposition of calcium in bones.

There are two main forms of Vitamin K: Vitamin K1 (phylloquinone), which is found primarily in green leafy vegetables and some vegetable oils, and Vitamin K2 (menaquinones), which is produced by bacteria in the intestines and is also found in some fermented foods.

Vitamin K deficiency can lead to bleeding disorders such as hemorrhage and excessive bruising. While Vitamin K deficiency is rare in adults, it can occur in newborns who have not yet developed sufficient levels of the vitamin. Therefore, newborns are often given a Vitamin K injection shortly after birth to prevent bleeding problems.

Thromboplastin is a substance that activates the coagulation cascade, leading to the formation of a clot (thrombus). It's primarily found in damaged or injured tissues and blood vessels, as well as in platelets (thrombocytes). There are two types of thromboplastin:

1. Extrinsic thromboplastin (also known as tissue factor): This is a transmembrane glycoprotein that is primarily found in subendothelial cells and released upon injury to the blood vessels. It initiates the extrinsic pathway of coagulation by binding to and activating Factor VII, ultimately leading to the formation of thrombin and fibrin clots.
2. Intrinsic thromboplastin (also known as plasma thromboplastin or factor III): This term is used less frequently and refers to a labile phospholipid component present in platelet membranes, which plays a role in the intrinsic pathway of coagulation.

In clinical settings, the term "thromboplastin" often refers to reagents used in laboratory tests like the prothrombin time (PT) and activated partial thromboplastin time (aPTT). These reagents contain a source of tissue factor and calcium ions to initiate and monitor the coagulation process.

Thrombin time (TT) is a medical laboratory test that measures the time it takes for a clot to form after thrombin, an enzyme that converts fibrinogen to fibrin in the final step of the coagulation cascade, is added to a plasma sample. This test is used to evaluate the efficiency of the conversion of fibrinogen to fibrin and can be used to detect the presence of abnormalities in the coagulation system, such as the presence of heparin or dysfibrinogenemia. Increased thrombin time may indicate the presence of a systemic anticoagulant or a deficiency in fibrinogen.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the activation of Factor X to Factor Xa, which is a critical step in the coagulation cascade.

When blood vessels are damaged, the coagulation cascade is initiated to prevent excessive bleeding. During this process, Factor V is activated by thrombin, another protein involved in coagulation, and then forms a complex with activated Factor X and calcium ions on the surface of platelets or other cells. This complex converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Deficiency or dysfunction of Factor V can lead to bleeding disorders such as hemophilia B or factor V deficiency, while mutations in the gene encoding Factor V can increase the risk of thrombosis, as seen in the Factor V Leiden mutation.

Disseminated Intravascular Coagulation (DIC) is a complex medical condition characterized by the abnormal activation of the coagulation cascade, leading to the formation of blood clots in small blood vessels throughout the body. This process can result in the consumption of clotting factors and platelets, which can then lead to bleeding complications. DIC can be caused by a variety of underlying conditions, including sepsis, trauma, cancer, and obstetric emergencies.

The term "disseminated" refers to the widespread nature of the clotting activation, while "intravascular" indicates that the clotting is occurring within the blood vessels. The condition can manifest as both bleeding and clotting complications, which can make it challenging to diagnose and manage.

The diagnosis of DIC typically involves laboratory tests that evaluate coagulation factors, platelet count, fibrin degradation products, and other markers of coagulation activation. Treatment is focused on addressing the underlying cause of the condition while also managing any bleeding or clotting complications that may arise.

Factor Xa is a serine protease that plays a crucial role in the coagulation cascade, which is a series of reactions that lead to the formation of a blood clot. It is one of the activated forms of Factor X, a pro-protein that is converted to Factor Xa through the action of other enzymes in the coagulation cascade.

Factor Xa functions as a key component of the prothrombinase complex, which also includes calcium ions, phospholipids, and activated Factor V (also known as Activated Protein C or APC). This complex is responsible for converting prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Inhibitors of Factor Xa are used as anticoagulants in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. These drugs work by selectively inhibiting Factor Xa, thereby preventing the formation of the prothrombinase complex and reducing the risk of clot formation.

Factor X is a protein that is essential for blood clotting, also known as coagulation. It is an enzyme that plays a crucial role in the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot. Factor X is activated by one of two pathways: the intrinsic pathway, which is initiated by damage to the blood vessels, or the extrinsic pathway, which is triggered by the release of tissue factor from damaged cells. Once activated, Factor X converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Inherited deficiencies in Factor X can lead to bleeding disorders, while increased levels of Factor X have been associated with an increased risk of thrombosis or blood clots. Therefore, maintaining appropriate levels of Factor X is important for the proper balance between bleeding and clotting in the body.

Hemostasis is the physiological process that occurs to stop bleeding (bleeding control) when a blood vessel is damaged. This involves the interaction of platelets, vasoconstriction, and blood clotting factors leading to the formation of a clot. The ultimate goal of hemostasis is to maintain the integrity of the vascular system while preventing excessive blood loss.

Factor VII, also known as proconvertin, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VII is synthesized in the liver and is activated when it comes into contact with tissue factor, which is exposed when blood vessels are damaged. Activated Factor VII then activates Factor X, leading to the formation of thrombin and ultimately a fibrin clot.

Inherited deficiencies or dysfunctions of Factor VII can lead to an increased risk of bleeding, while elevated levels of Factor VII have been associated with an increased risk of thrombosis (blood clots).

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

Fibrinogen is a soluble protein present in plasma, synthesized by the liver. It plays an essential role in blood coagulation. When an injury occurs, fibrinogen gets converted into insoluble fibrin by the action of thrombin, forming a fibrin clot that helps to stop bleeding from the injured site. Therefore, fibrinogen is crucial for hemostasis, which is the process of stopping bleeding and starting the healing process after an injury.

Acenocoumarol is an anticoagulant medication that is used to prevent and treat blood clots. It works by inhibiting the formation of vitamin K-dependent clotting factors, which are necessary for normal blood coagulation. This results in a prolonged bleeding time and reduced risk of blood clots.

Acenocoumarol is a coumarin derivative and is available under various brand names, including Sintrom and Nicoumalone. It is typically administered orally in the form of tablets and its effects are monitored through regular blood tests to ensure that the dosage is appropriate and that the risk of bleeding complications is minimized.

Common side effects of acenocoumarol include easy bruising, nosebleeds, and skin rashes. It may also interact with a variety of other medications, including antibiotics, antifungals, and certain herbal supplements, so it is important to inform your healthcare provider of all medications and supplements you are taking before starting acenocoumarol therapy.

It is important to note that acenocoumarol has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic dose is relatively small. Therefore, it is essential to follow your healthcare provider's instructions carefully when taking this medication and to have regular blood tests to monitor its effects on your coagulation status.

Thrombophilia is a medical condition characterized by an increased tendency to form blood clots (thrombi) due to various genetic or acquired abnormalities in the coagulation system. These abnormalities can lead to a hypercoagulable state, which can cause thrombosis in both veins and arteries. Commonly identified thrombophilias include factor V Leiden mutation, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, and protein S deficiency.

Acquired thrombophilias can be caused by various factors such as antiphospholipid antibody syndrome (APS), malignancies, pregnancy, oral contraceptive use, hormone replacement therapy, and certain medical conditions like inflammatory bowel disease or nephrotic syndrome.

It is essential to diagnose thrombophilia accurately, as it may influence the management of venous thromboembolism (VTE) events and guide decisions regarding prophylactic anticoagulation in high-risk situations.

4-Hydroxycoumarins are a type of chemical compound that contains a hydroxy group (-OH) attached to the 4th carbon atom of the coumarin structure. Coumarins themselves are aromatic organic compounds, characterized by a benzene ring fused to a pyrone ring.

4-Hydroxycoumarins have gained attention in medical research due to their potential biological activities. For instance, some 4-hydroxycoumarins exhibit anticoagulant properties and are used as oral anticoagulant drugs, such as warfarin. These compounds work by inhibiting the vitamin K epoxide reductase enzyme, thereby interfering with the blood clotting process.

Additionally, 4-hydroxycoumarins have been investigated for their potential anticancer, anti-inflammatory, and antibacterial activities. However, more research is needed to fully understand their therapeutic potential and safety profiles.

A platelet count is a laboratory test that measures the number of platelets, also known as thrombocytes, in a sample of blood. Platelets are small, colorless cell fragments that circulate in the blood and play a crucial role in blood clotting. They help to stop bleeding by sticking together to form a plug at the site of an injured blood vessel.

A normal platelet count ranges from 150,000 to 450,000 platelets per microliter (µL) of blood. A lower than normal platelet count is called thrombocytopenia, while a higher than normal platelet count is known as thrombocytosis.

Abnormal platelet counts can be a sign of various medical conditions, including bleeding disorders, infections, certain medications, and some types of cancer. It is important to consult with a healthcare provider if you have any concerns about your platelet count or if you experience symptoms such as easy bruising, prolonged bleeding, or excessive menstrual flow.

Freeze-drying, also known as lyophilization, is a method of preservation that involves the removal of water from a frozen product by sublimation, which is the direct transition of a solid to a gas. This process allows for the preservation of the original shape and structure of the material while significantly extending its shelf life. In medical contexts, freeze-drying can be used for various purposes, including the long-term storage of pharmaceuticals, vaccines, and diagnostic samples. The process helps maintain the efficacy and integrity of these materials until they are ready to be reconstituted with water and used.

In the context of medicine, plasma refers to the clear, yellowish fluid that is the liquid component of blood. It's composed of water, enzymes, hormones, antibodies, clotting factors, and other proteins. Plasma serves as a transport medium for cells, nutrients, waste products, gases, and other substances throughout the body. Additionally, it plays a crucial role in the immune response and helps regulate various bodily functions.

Plasma can be collected from blood donors and processed into various therapeutic products, such as clotting factors for people with hemophilia or immunoglobulins for patients with immune deficiencies. This process is called plasma fractionation.

Hemorrhagic disorders are medical conditions characterized by abnormal bleeding due to impaired blood clotting. This can result from deficiencies in coagulation factors, platelet dysfunction, or the use of medications that interfere with normal clotting processes. Examples include hemophilia, von Willebrand disease, and disseminated intravascular coagulation (DIC). Treatment often involves replacing the missing clotting factor or administering medications to help control bleeding.

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the conversion of prothrombin to thrombin, which is a critical step in the coagulation process.

Inherited deficiencies or abnormalities in Factor V can lead to bleeding disorders. For example, Factor V Leiden is a genetic mutation that causes an increased risk of blood clots, while Factor V deficiency can cause a bleeding disorder.

It's worth noting that "Factor Va" is not a standard medical term. Factor V becomes activated and turns into Factor Va during the coagulation cascade. Therefore, it is possible that you are looking for the definition of "Factor Va" in the context of its role as an activated form of Factor V in the coagulation process.

Bilirubin is a yellowish pigment that is produced by the liver when it breaks down old red blood cells. It is a normal byproduct of hemoglobin metabolism and is usually conjugated (made water-soluble) in the liver before being excreted through the bile into the digestive system. Elevated levels of bilirubin can cause jaundice, a yellowing of the skin and eyes. Increased bilirubin levels may indicate liver disease or other medical conditions such as gallstones or hemolysis. It is also measured to assess liver function and to help diagnose various liver disorders.

Thromboelastography (TEG) is a viscoelastic method used to assess the kinetics of clot formation, clot strength, and fibrinolysis in whole blood. It provides a global assessment of hemostasis by measuring the mechanical properties of a clot as it forms and dissolves over time. The TEG graph displays several parameters that reflect the different stages of clotting, including reaction time (R), clot formation time (K), angle of clot formation (α), maximum amplitude (MA), and percentage lysis at 30 minutes (LY30). These parameters can help guide transfusion therapy and inform decisions regarding the management of coagulopathy in various clinical settings, such as trauma, cardiac surgery, liver transplantation, and obstetrics.

Cefotetan is a type of antibiotic known as a cephalosporin, which is used to treat various bacterial infections. It works by interfering with the bacteria's ability to form a cell wall, leading to the death of the bacteria. Cefotetan has a broad spectrum of activity and is effective against many different types of gram-positive and gram-negative bacteria.

Cefotetan is often used to treat intra-abdominal infections, gynecological infections, skin and soft tissue infections, and bone and joint infections. It is administered intravenously or intramuscularly, and the dosage and duration of treatment will depend on the type and severity of the infection being treated.

Like all antibiotics, cefotetan can cause side effects, including diarrhea, nausea, vomiting, and allergic reactions. It may also increase the risk of bleeding, particularly in patients with impaired kidney function or those taking blood thinners. Therefore, it is important to be closely monitored by a healthcare provider while taking this medication.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

Protein C is a vitamin K-dependent protease that functions as an important regulator of coagulation and inflammation. It is a plasma protein produced in the liver that, when activated, degrades clotting factors Va and VIIIa to limit thrombus formation and prevent excessive blood clotting. Protein C also has anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and reducing endothelial cell activation. Inherited or acquired deficiencies in Protein C can lead to an increased risk of thrombosis, a condition characterized by abnormal blood clot formation within blood vessels.

Point-of-care (POC) systems refer to medical diagnostic tests or tools that are performed at or near the site where a patient receives care, such as in a doctor's office, clinic, or hospital room. These systems provide rapid and convenient results, allowing healthcare professionals to make immediate decisions regarding diagnosis, treatment, and management of a patient's condition.

POC systems can include various types of diagnostic tests, such as:

1. Lateral flow assays (LFAs): These are paper-based devices that use capillary action to detect the presence or absence of a target analyte in a sample. Examples include pregnancy tests and rapid strep throat tests.
2. Portable analyzers: These are compact devices used for measuring various parameters, such as blood glucose levels, coagulation status, or electrolytes, using small volumes of samples.
3. Imaging systems: Handheld ultrasound machines and portable X-ray devices fall under this category, providing real-time imaging at the point of care.
4. Monitoring devices: These include continuous glucose monitors, pulse oximeters, and blood pressure cuffs that provide real-time data to help manage patient conditions.

POC systems offer several advantages, such as reduced turnaround time for test results, decreased need for sample transportation, and increased patient satisfaction due to faster decision-making and treatment initiation. However, it is essential to ensure the accuracy and reliability of these tests by following proper testing procedures and interpreting results correctly.

Coagulants are substances that promote the process of coagulation or clotting. They are often used in medical settings to help control bleeding and promote healing. Coagulants work by encouraging the formation of a clot, which helps to stop the flow of blood from a wound or cut.

There are several different types of coagulants that may be used in medical treatments. Some coagulants are naturally occurring substances, such as vitamin K, which is essential for the production of certain clotting factors in the body. Other coagulants may be synthetic or semi-synthetic compounds, such as recombinant activated factor VII (rFVIIa), which is used to treat bleeding disorders and prevent excessive bleeding during surgery.

Coagulants are often administered through injection or infusion, but they can also be applied topically to wounds or cuts. In some cases, coagulants may be used in combination with other treatments, such as compression or cauterization, to help control bleeding and promote healing.

It is important to note that while coagulants can be helpful in controlling bleeding and promoting healing, they can also increase the risk of blood clots and other complications. As a result, they should only be used under the guidance and supervision of a qualified healthcare professional.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

Vitamin K1, also known as phylloquinone, is a type of fat-soluble vitamin K. It is the primary form of Vitamin K found in plants, particularly in green leafy vegetables such as kale, spinach, and collard greens. Vitamin K1 plays a crucial role in blood clotting and helps to prevent excessive bleeding by assisting in the production of several proteins involved in this process. It is also essential for maintaining healthy bones by aiding in the regulation of calcium deposition in bone tissue. A deficiency in Vitamin K1 can lead to bleeding disorders and, in some cases, osteoporosis.

Antithrombins are substances that prevent the formation or promote the dissolution of blood clots (thrombi). They include:

1. Anticoagulants: These are medications that reduce the ability of the blood to clot. Examples include heparin, warfarin, and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.
2. Thrombolytic agents: These are medications that break down existing blood clots. Examples include alteplase, reteplase, and tenecteplase.
3. Fibrinolytics: These are a type of thrombolytic agent that specifically target fibrin, a protein involved in the formation of blood clots.
4. Natural anticoagulants: These are substances produced by the body to regulate blood clotting. Examples include antithrombin III, protein C, and protein S.

Antithrombins are used in the prevention and treatment of various thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). It is important to note that while antithrombins can help prevent or dissolve blood clots, they also increase the risk of bleeding, so their use must be carefully monitored.

Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a clot forms in an artery, it can cut off the supply of oxygen and nutrients to the tissues served by that artery, leading to damage or tissue death. If a thrombus forms in the heart, it can cause a heart attack. If a thrombus breaks off and travels through the bloodstream, it can lodge in a smaller vessel, causing blockage and potentially leading to damage in the organ that the vessel supplies. This is known as an embolism.

Thrombosis can occur due to various factors such as injury to the blood vessel wall, abnormalities in blood flow, or changes in the composition of the blood. Certain medical conditions, medications, and lifestyle factors can increase the risk of thrombosis. Treatment typically involves anticoagulant or thrombolytic therapy to dissolve or prevent further growth of the clot, as well as addressing any underlying causes.

Fibrinolysis is the natural process in the body that leads to the dissolution of blood clots. It is a vital part of hemostasis, the process that regulates bleeding and wound healing. Fibrinolysis occurs when plasminogen activators convert plasminogen to plasmin, an enzyme that breaks down fibrin, the insoluble protein mesh that forms the structure of a blood clot. This process helps to prevent excessive clotting and maintains the fluidity of the blood. In medical settings, fibrinolysis can also refer to the therapeutic use of drugs that stimulate this process to dissolve unwanted or harmful blood clots, such as those that cause deep vein thrombosis or pulmonary embolism.

Liver function tests (LFTs) are a group of blood tests that are used to assess the functioning and health of the liver. These tests measure the levels of various enzymes, proteins, and waste products that are produced or metabolized by the liver. Some common LFTs include:

1. Alanine aminotransferase (ALT): An enzyme found primarily in the liver, ALT is released into the bloodstream in response to liver cell damage. Elevated levels of ALT may indicate liver injury or disease.
2. Aspartate aminotransferase (AST): Another enzyme found in various tissues, including the liver, heart, and muscles. Like ALT, AST is released into the bloodstream following tissue damage. High AST levels can be a sign of liver damage or other medical conditions.
3. Alkaline phosphatase (ALP): An enzyme found in several organs, including the liver, bile ducts, and bones. Elevated ALP levels may indicate a blockage in the bile ducts, liver disease, or bone disorders.
4. Gamma-glutamyl transferase (GGT): An enzyme found mainly in the liver, pancreas, and biliary system. Increased GGT levels can suggest liver disease, alcohol consumption, or the use of certain medications.
5. Bilirubin: A yellowish pigment produced when hemoglobin from red blood cells is broken down. Bilirubin is processed by the liver and excreted through bile. High bilirubin levels can indicate liver dysfunction, bile duct obstruction, or certain types of anemia.
6. Albumin: A protein produced by the liver that helps maintain fluid balance in the body and transports various substances in the blood. Low albumin levels may suggest liver damage, malnutrition, or kidney disease.
7. Total protein: A measure of all proteins present in the blood, including albumin and other types of proteins produced by the liver. Decreased total protein levels can indicate liver dysfunction or other medical conditions.

These tests are often ordered together as part of a routine health checkup or when evaluating symptoms related to liver function or disease. The results should be interpreted in conjunction with clinical findings, medical history, and other diagnostic tests.

1-Carboxyglutamic acid, also known as γ-carboxyglutamic acid, is a post-translational modification found on certain blood clotting factors and other calcium-binding proteins. It is formed by the carboxylation of glutamic acid residues in these proteins, which enhances their ability to bind to calcium ions. This modification is essential for the proper functioning of many physiological processes, including blood coagulation, bone metabolism, and wound healing.

Fibrin(ogen) degradation products (FDPs) are a group of proteins that result from the breakdown of fibrinogen and fibrin, which are key components of blood clots. This process occurs during the normal physiological process of fibrinolysis, where clots are dissolved to maintain blood flow.

FDPs can be measured in the blood as a marker for the activation of the coagulation and fibrinolytic systems. Elevated levels of FDPs may indicate the presence of a disorder that causes abnormal clotting or bleeding, such as disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of cancer.

It is important to note that FDPs are not specific to any particular disorder and their measurement should be interpreted in conjunction with other clinical and laboratory findings.

Thromboembolism is a medical condition that refers to the obstruction of a blood vessel by a thrombus (blood clot) that has formed elsewhere in the body and then been transported by the bloodstream to a narrower vessel, where it becomes lodged. This process can occur in various parts of the body, leading to different types of thromboembolisms:

1. Deep Vein Thrombosis (DVT): A thrombus forms in the deep veins, usually in the legs or pelvis, and then breaks off and travels to the lungs, causing a pulmonary embolism.
2. Pulmonary Embolism (PE): A thrombus formed elsewhere, often in the deep veins of the legs, dislodges and travels to the lungs, blocking one or more pulmonary arteries. This can lead to shortness of breath, chest pain, and potentially life-threatening complications if not treated promptly.
3. Cerebral Embolism: A thrombus formed in another part of the body, such as the heart or carotid artery, dislodges and travels to the brain, causing a stroke or transient ischemic attack (TIA).
4. Arterial Thromboembolism: A thrombus forms in an artery and breaks off, traveling to another part of the body and blocking blood flow to an organ or tissue, leading to potential damage or loss of function. Examples include mesenteric ischemia (intestinal damage due to blocked blood flow) and retinal artery occlusion (vision loss due to blocked blood flow in the eye).

Prevention, early detection, and appropriate treatment are crucial for managing thromboembolism and reducing the risk of severe complications.

Fibrinopeptide A is a small protein molecule that is cleaved and released from the larger fibrinogen protein during the blood clotting process. Specifically, it is removed by the enzyme thrombin as part of the conversion of fibrinogen to fibrin, which is the main structural component of a blood clot. The measurement of Fibrinopeptide A in the blood can be used as a marker for ongoing thrombin activation and fibrin formation, which are key events in coagulation and hemostasis. Increased levels of Fibrinopeptide A may indicate abnormal or excessive blood clotting, such as in disseminated intravascular coagulation (DIC) or deep vein thrombosis (DVT).

Factor IX is also known as Christmas factor, which is a protein that plays a crucial role in the coagulation cascade, a series of chemical reactions that leads to the formation of a blood clot. It is one of the essential components required for the proper functioning of the body's natural blood-clotting mechanism.

Factor IX is synthesized in the liver and activated when it comes into contact with an injured blood vessel. Once activated, it collaborates with other factors to convert factor X to its active form, which then converts prothrombin to thrombin. Thrombin is responsible for converting fibrinogen to fibrin, forming a stable fibrin clot that helps stop bleeding and promote healing.

Deficiencies in Factor IX can lead to hemophilia B, a genetic disorder characterized by prolonged bleeding and an increased risk of spontaneous bleeding. Hemophilia B is inherited in an X-linked recessive pattern, meaning it primarily affects males, while females serve as carriers of the disease. Treatment for hemophilia B typically involves replacing the missing or deficient Factor IX through infusions to prevent or manage bleeding episodes.

Factor VIIa is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VIIa is the activated form of factor VII, which is normally activated by tissue factor (TF) when there is damage to the blood vessels. Together, TF and Factor VIIa convert Factor X to its active form, Factor Xa, which then converts prothrombin to thrombin, leading to the formation of a fibrin clot.

In summary, Factor VIIa is an important protein in the coagulation cascade that helps to initiate the formation of a blood clot in response to injury.

In the context of medicine and medical devices, calibration refers to the process of checking, adjusting, or confirming the accuracy of a measurement instrument or system. This is typically done by comparing the measurements taken by the device being calibrated to those taken by a reference standard of known accuracy. The goal of calibration is to ensure that the medical device is providing accurate and reliable measurements, which is critical for making proper diagnoses and delivering effective treatment. Regular calibration is an important part of quality assurance and helps to maintain the overall performance and safety of medical devices.

I'm sorry for any confusion, but "Lupus Coagulation Inhibitor" is not a recognized medical term or concept in hematology or immunology.

Systemic Lupus Erythematosus (SLE), often referred to simply as lupus, is an autoimmune disease where the body's immune system mistakenly attacks healthy tissue. However, this does not result in a specific coagulation inhibitor.

If you're asking about lupus anticoagulants, these are antibodies that can interfere with clotting tests but paradoxically increase the risk of blood clots in vivo. They are sometimes seen in patients with SLE and other autoimmune diseases.

Please provide more context if you meant something else, so I can give a more accurate response.

Fat substitutes are substances that are used in food production to mimic the taste, texture, and other sensory properties of fat, while providing fewer calories or no calories at all. They can be derived from natural sources, such as carbohydrates or proteins, or synthesized in a lab.

Fat substitutes can be classified into three main categories:

1. Macronutrient-based fat substitutes: These are made up of carbohydrates, proteins, or fiber that provide fewer calories than fat. Examples include maltodextrin, modified food starch, and whey protein concentrate.
2. Fat-based fat substitutes: These are made up of fat molecules that have been chemically altered to reduce their calorie content. Examples include olestra (sucrose polyester) and caprenin.
3. Non-nutritive fat substitutes: These provide no calories or nutrients and are often used in small amounts to enhance the texture and taste of food. Examples include cellulose gel, microcrystalline cellulose, and silica.

Fat substitutes can be useful for people who are trying to reduce their calorie intake, maintain a healthy weight, or manage certain medical conditions such as diabetes or high cholesterol. However, it's important to note that fat substitutes should not replace all dietary fats, as some fats are essential for good health. It's also important to read food labels carefully and consume fat substitutes in moderation, as they may have other negative effects on health if consumed in excess.

Moxalactam is not a medical condition but actually an antibiotic medication. It is a type of beta-lactam antibiotic, specifically a fourth-generation cephalosporin, which is used to treat various bacterial infections. Moxalactam has a broad spectrum of activity against both Gram-positive and Gram-negative bacteria, including many that are resistant to other antibiotics.

Moxalactam works by inhibiting the synthesis of the bacterial cell wall, leading to bacterial death. It is commonly used to treat intra-abdominal infections, urinary tract infections, pneumonia, and sepsis, among other conditions. As with any medication, moxalactam can have side effects, including gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as allergic reactions and changes in liver function tests. It is important to use antibiotics only when necessary and under the guidance of a healthcare professional to minimize the development of antibiotic resistance.

Coumarins are a class of organic compounds that occur naturally in certain plants, such as sweet clover and tonka beans. They have a characteristic aroma and are often used as fragrances in perfumes and flavorings in food products. In addition to their use in consumer goods, coumarins also have important medical applications.

One of the most well-known coumarins is warfarin, which is a commonly prescribed anticoagulant medication used to prevent blood clots from forming or growing larger. Warfarin works by inhibiting the activity of vitamin K-dependent clotting factors in the liver, which helps to prolong the time it takes for blood to clot.

Other medical uses of coumarins include their use as anti-inflammatory agents and antimicrobial agents. Some coumarins have also been shown to have potential cancer-fighting properties, although more research is needed in this area.

It's important to note that while coumarins have many medical uses, they can also be toxic in high doses. Therefore, it's essential to use them only under the guidance of a healthcare professional.

Liver diseases refer to a wide range of conditions that affect the normal functioning of the liver. The liver is a vital organ responsible for various critical functions such as detoxification, protein synthesis, and production of biochemicals necessary for digestion.

Liver diseases can be categorized into acute and chronic forms. Acute liver disease comes on rapidly and can be caused by factors like viral infections (hepatitis A, B, C, D, E), drug-induced liver injury, or exposure to toxic substances. Chronic liver disease develops slowly over time, often due to long-term exposure to harmful agents or inherent disorders of the liver.

Common examples of liver diseases include hepatitis, cirrhosis (scarring of the liver tissue), fatty liver disease, alcoholic liver disease, autoimmune liver diseases, genetic/hereditary liver disorders (like Wilson's disease and hemochromatosis), and liver cancers. Symptoms may vary widely depending on the type and stage of the disease but could include jaundice, abdominal pain, fatigue, loss of appetite, nausea, and weight loss.

Early diagnosis and treatment are essential to prevent progression and potential complications associated with liver diseases.

Surgical hemostasis refers to the methods and techniques used during surgical procedures to stop bleeding or prevent hemorrhage. This can be achieved through various means, including the use of surgical instruments such as clamps, ligatures, or staples to physically compress blood vessels and stop the flow of blood. Electrosurgical tools like cautery may also be used to coagulate and seal off bleeding vessels using heat. Additionally, topical hemostatic agents can be applied to promote clotting and control bleeding in wounded tissues. Effective surgical hemostasis is crucial for ensuring a successful surgical outcome and minimizing the risk of complications such as excessive blood loss, infection, or delayed healing.

Drug monitoring, also known as therapeutic drug monitoring (TDM), is a medical practice that involves testing blood or other bodily fluids to determine the concentration of a particular medication. This information is used to ensure that the patient is receiving an appropriate dosage and to help guide adjustments in medication therapy. It can be especially important for medications with a narrow therapeutic index, meaning that there is a small range between the effective dose and a toxic dose.

The goal of drug monitoring is to optimize medication effectiveness while minimizing potential side effects. This may involve measuring the concentration of a drug at various times after dosing to determine how quickly it is being metabolized or eliminated from the body, as well as to assess compliance with the prescribed treatment regimen.

Drug monitoring can be performed using a variety of methods, including immunoassays, chromatography, and mass spectrometry. The specific method used will depend on the drug being monitored and the level of sensitivity required. Results from drug monitoring tests are typically interpreted in conjunction with other clinical information, such as the patient's age, weight, renal function, liver function, and overall health status.

Protein S is a vitamin K-dependent protein found in the blood that functions as a natural anticoagulant. It plays a crucial role in regulating the body's clotting system by inhibiting the activation of coagulation factors, thereby preventing excessive blood clotting. Protein S also acts as a cofactor for activated protein C, which is another important anticoagulant protein.

Protein S exists in two forms: free and bound to a protein called C4b-binding protein (C4BP). Only the free form of Protein S has biological activity in inhibiting coagulation. Inherited or acquired deficiencies in Protein S can lead to an increased risk of thrombosis, or abnormal blood clot formation, which can cause various medical conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Regular monitoring of Protein S levels is essential for patients with a history of thrombotic events or those who have a family history of thrombophilia.

Dicumarol is an anticoagulant medication that belongs to a class of compounds known as coumarins. It works by inhibiting the action of vitamin K, which is necessary for the production of certain clotting factors in the liver. This results in a decrease in blood clotting ability and helps prevent the formation of harmful blood clots.

Dicumarol is primarily used to treat and prevent deep vein thrombosis (DVT), pulmonary embolism, and other conditions that may require anticoagulation therapy. It is also used in the management of atrial fibrillation, valvular heart disease, and certain types of heart attacks.

It's important to note that dicumarol has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic dose is relatively small. Therefore, it requires careful monitoring of blood clotting times (INR) to ensure that the drug is working effectively without causing excessive bleeding.

Dicumarol is available in oral form and is typically taken once or twice daily. Common side effects include nausea, vomiting, diarrhea, skin rash, and abnormal liver function tests. Rare but serious side effects include severe bleeding, necrosis of the skin and other tissues, and allergic reactions.

Dicumarol is a prescription medication that should only be used under the guidance of a healthcare professional. It interacts with many other medications and foods, so it's important to inform your doctor about all the drugs you are taking and any dietary changes you may make while on this medication.

Acute liver failure is a sudden and severe loss of liver function that occurs within a few days or weeks. It can be caused by various factors such as drug-induced liver injury, viral hepatitis, or metabolic disorders. In acute liver failure, the liver cannot perform its vital functions, including protein synthesis, detoxification, and metabolism of carbohydrates, fats, and proteins.

The symptoms of acute liver failure include jaundice (yellowing of the skin and eyes), coagulopathy (bleeding disorders), hepatic encephalopathy (neurological symptoms such as confusion, disorientation, and coma), and elevated levels of liver enzymes in the blood. Acute liver failure is a medical emergency that requires immediate hospitalization and treatment, which may include medications, supportive care, and liver transplantation.

Liver cirrhosis is a chronic, progressive disease characterized by the replacement of normal liver tissue with scarred (fibrotic) tissue, leading to loss of function. The scarring is caused by long-term damage from various sources such as hepatitis, alcohol abuse, nonalcoholic fatty liver disease, and other causes. As the disease advances, it can lead to complications like portal hypertension, fluid accumulation in the abdomen (ascites), impaired brain function (hepatic encephalopathy), and increased risk of liver cancer. It is generally irreversible, but early detection and treatment of underlying causes may help slow down its progression.

Factor X deficiency, also known as Stuart-Prower factor deficiency, is a rare bleeding disorder that affects the body's ability to form blood clots. It is caused by a mutation in the gene that provides instructions for making coagulation factor X, a protein involved in the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot.

People with factor X deficiency may experience excessive bleeding after injury or surgery, and they may also have an increased risk of spontaneous bleeding, such as nosebleeds, heavy menstrual periods, and joint bleeds. The severity of the condition can vary widely, from mild to severe, depending on the level of factor X activity in the blood.

Factor X deficiency can be inherited or acquired. Inherited forms of the disorder are caused by mutations in the F10 gene and are usually present at birth. Acquired forms of the disorder can develop later in life due to conditions such as liver disease, vitamin K deficiency, or the use of certain medications that interfere with coagulation.

Treatment for factor X deficiency typically involves replacement therapy with fresh frozen plasma or recombinant factor X concentrates to help restore normal clotting function. In some cases, other treatments such as antifibrinolytic agents or desmopressin may also be used to manage bleeding symptoms.

Factor VIII is a protein in the blood that is essential for normal blood clotting. It is also known as antihemophilic factor (AHF). Deficiency or dysfunction of this protein results in hemophilia A, a genetic disorder characterized by prolonged bleeding and easy bruising. Factor VIII works together with other proteins to help form a clot and stop bleeding at the site of an injury. It acts as a cofactor for another clotting factor, IX, in the so-called intrinsic pathway of blood coagulation. Intravenous infusions of Factor VIII concentrate are used to treat and prevent bleeding episodes in people with hemophilia A.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

Venous thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) in the deep veins, often in the legs (deep vein thrombosis or DVT), but it can also occur in other parts of the body such as the arms, pelvis, or lungs (pulmonary embolism).

The formation of a venous thrombus can be caused by various factors, including injury to the blood vessel wall, changes in blood flow, and alterations in the composition of the blood. These factors can lead to the activation of clotting factors and platelets, which can result in the formation of a clot that blocks the vein.

Symptoms of venous thrombosis may include swelling, pain, warmth, and redness in the affected area. In some cases, the clot can dislodge and travel to other parts of the body, causing potentially life-threatening complications such as pulmonary embolism.

Risk factors for venous thrombosis include advanced age, obesity, smoking, pregnancy, use of hormonal contraceptives or hormone replacement therapy, cancer, recent surgery or trauma, prolonged immobility, and a history of previous venous thromboembolism. Treatment typically involves the use of anticoagulant medications to prevent further clotting and dissolve existing clots.

Rodenticides are a type of pesticide that are specifically designed to control or kill rodents, such as rats and mice. They contain chemicals that can interfere with the normal physiology of rodents, leading to their death. Rodenticides can come in various forms, including powders, pellets, and liquids, and they can be placed in bait stations or used in conjunction with other pest control methods.

It is important to use rodenticides carefully and only as directed, as they can also pose a risk to non-target animals, including pets and wildlife, if not used properly. Additionally, some rodenticides contain chemicals that can accumulate in the body over time and cause harm to humans if they are exposed to them repeatedly or in large quantities. As such, it is important to follow all safety guidelines when using rodenticides and to store them out of reach of children and pets.

Aspartate aminotransferases (ASTs) are a group of enzymes found in various tissues throughout the body, including the heart, liver, and muscles. They play a crucial role in the metabolic process of transferring amino groups between different molecules.

In medical terms, AST is often used as a blood test to measure the level of this enzyme in the serum. Elevated levels of AST can indicate damage or injury to tissues that contain this enzyme, such as the liver or heart. For example, liver disease, including hepatitis and cirrhosis, can cause elevated AST levels due to damage to liver cells. Similarly, heart attacks can also result in increased AST levels due to damage to heart muscle tissue.

It is important to note that an AST test alone cannot diagnose a specific medical condition, but it can provide valuable information when used in conjunction with other diagnostic tests and clinical evaluation.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Chromogenic compounds are substances that can be converted into a colored product through a chemical reaction. These compounds are often used in various diagnostic tests, including microbiological assays and immunoassays, to detect the presence or absence of a specific analyte (such as a particular bacterium, enzyme, or antigen).

In these tests, a chromogenic substrate is added to the sample, and if the target analyte is present, it will react with the substrate and produce a colored product. The intensity of the color can often be correlated with the amount of analyte present in the sample, allowing for quantitative analysis.

Chromogenic compounds are widely used in clinical laboratories because they offer several advantages over other types of diagnostic tests. They are typically easy to use and interpret, and they can provide rapid results with high sensitivity and specificity. Additionally, chromogenic assays can be automated, which can help increase throughput and reduce the potential for human error.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Liver transplantation is a surgical procedure in which a diseased or failing liver is replaced with a healthy one from a deceased donor or, less commonly, a portion of a liver from a living donor. The goal of the procedure is to restore normal liver function and improve the patient's overall health and quality of life.

Liver transplantation may be recommended for individuals with end-stage liver disease, acute liver failure, certain genetic liver disorders, or liver cancers that cannot be treated effectively with other therapies. The procedure involves complex surgery to remove the diseased liver and implant the new one, followed by a period of recovery and close medical monitoring to ensure proper function and minimize the risk of complications.

The success of liver transplantation has improved significantly in recent years due to advances in surgical techniques, immunosuppressive medications, and post-transplant care. However, it remains a major operation with significant risks and challenges, including the need for lifelong immunosuppression to prevent rejection of the new liver, as well as potential complications such as infection, bleeding, and organ failure.

Tosylarginine Methyl Ester (TAME) is not a medication or a therapeutic agent, but it is a research compound used in scientific studies. It is a synthetic molecule that is often used as a control or a reference standard in enzyme inhibition assays. TAME is an esterified form of the amino acid arginine, with a tosyl group (p-toluenesulfonyl) attached to the nitrogen atom.

TAME is specifically used as a selective and reversible inhibitor of the enzyme called butyrylcholinesterase (BChE), which is involved in the breakdown of certain neurotransmitters in the body. By inhibiting BChE, TAME can help to increase the levels of these neurotransmitters in the brain, making it a useful tool for studying the mechanisms of this enzyme and its role in various physiological processes.

It's important to note that while TAME is used in research settings, it is not approved for use as a drug or therapeutic agent in humans or animals.

Liver failure is a serious condition in which the liver is no longer able to perform its normal functions, such as removing toxins and waste products from the blood, producing bile to help digest food, and regulating blood clotting. This can lead to a buildup of toxins in the body, jaundice (yellowing of the skin and eyes), fluid accumulation in the abdomen, and an increased risk of bleeding. Liver failure can be acute (sudden) or chronic (developing over time). Acute liver failure is often caused by medication toxicity, viral hepatitis, or other sudden illnesses. Chronic liver failure is most commonly caused by long-term damage from conditions such as cirrhosis, hepatitis, alcohol abuse, and non-alcoholic fatty liver disease.

It's important to note that Liver Failure is a life threatening condition and need immediate medical attention.

Fibrin is defined as a protein that is formed from fibrinogen during the clotting of blood. It plays an essential role in the formation of blood clots, also known as a clotting or coagulation cascade. When an injury occurs and bleeding starts, fibrin threads form a net-like structure that entraps platelets and red blood cells to create a stable clot, preventing further loss of blood.

The process of forming fibrin from fibrinogen is initiated by thrombin, another protein involved in the coagulation cascade. Thrombin cleaves fibrinogen into fibrin monomers, which then polymerize to form long strands of fibrin. These strands cross-link with each other through a process catalyzed by factor XIIIa, forming a stable clot that protects the wound and promotes healing.

It is important to note that abnormalities in fibrin formation or breakdown can lead to bleeding disorders or thrombotic conditions, respectively. Proper regulation of fibrin production and degradation is crucial for maintaining healthy hemostasis and preventing excessive clotting or bleeding.

Factor XII deficiency, also known as Hageman factor deficiency, is a rare genetic disorder characterized by a lack or dysfunction of coagulation factor XII. This protein is involved in the initiation of the coagulation cascade, which leads to the formation of a blood clot. People with Factor XII deficiency may have an increased risk of bleeding, but it is typically mild and not life-threatening. The diagnosis is usually made through blood tests that measure the level and function of Factor XII. Treatment is generally not necessary unless there is significant bleeding, in which case fresh frozen plasma or cryoprecipitate may be given to provide temporary correction of the deficiency. It's important to note that Factor XII deficiency is not a common cause of bleeding disorders and it doesn't increase the risk of thrombosis.

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with liver dysfunction and/or portosystemic shunting. It results from the accumulation of toxic substances, such as ammonia and inflammatory mediators, which are normally metabolized by the liver. HE can present with a wide range of symptoms, including changes in sleep-wake cycle, altered mental status, confusion, disorientation, asterixis (flapping tremor), and in severe cases, coma. The diagnosis is based on clinical evaluation, neuropsychological testing, and exclusion of other causes of cognitive impairment. Treatment typically involves addressing the underlying liver dysfunction, reducing ammonia production through dietary modifications and medications, and preventing further episodes with lactulose or rifaximin therapy.

A blood component transfusion is the process of transferring a specific component of donated blood into a recipient's bloodstream. Blood components include red blood cells, plasma, platelets, and cryoprecipitate (a fraction of plasma that contains clotting factors). These components can be separated from whole blood and stored separately to allow for targeted transfusions based on the individual needs of the patient.

For example, a patient who is anemic may only require a red blood cell transfusion, while a patient with severe bleeding may need both red blood cells and plasma to replace lost volume and clotting factors. Platelet transfusions are often used for patients with low platelet counts or platelet dysfunction, and cryoprecipitate is used for patients with factor VIII or fibrinogen deficiencies.

Blood component transfusions must be performed under strict medical supervision to ensure compatibility between the donor and recipient blood types and to monitor for any adverse reactions. Proper handling, storage, and administration of blood components are also critical to ensure their safety and efficacy.

Hematologic tests, also known as hematology tests, are a group of diagnostic exams that evaluate the health and function of different components of blood, such as red and white blood cells, platelets, and clotting factors. These tests can detect various disorders, including anemia, infection, bleeding problems, and several types of cancer. Common hematologic tests include complete blood count (CBC), coagulation studies, peripheral smear examination, and erythrocyte sedimentation rate (ESR). The specific test or combination of tests ordered will depend on the patient's symptoms, medical history, and physical examination findings.

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

Pipicolic acid is not a term that refers to a specific medical condition or disease. Instead, it is a metabolite that is involved in the body's metabolic processes.

Pipicolic acid is a type of organic compound called a cyclic amino acid, which is derived from the amino acid lysine. It is produced in the liver and is excreted in urine. Pipicolic acid has been found to have various functions in the body, including regulating the metabolism of lipids and bile acids.

Abnormal levels of pipicolic acid in the body may be associated with certain medical conditions, such as liver disease or genetic disorders that affect amino acid metabolism. However, pipicolic acid is not typically used as a diagnostic marker for these conditions.

In summary, pipicolic acid is a cyclic amino acid produced in the liver and involved in various metabolic processes in the body. Abnormal levels of pipicolic acid may be associated with certain medical conditions but are not typically used as diagnostic markers.

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. This results in impaired blood clotting and prolonged bleeding, particularly after injuries or surgeries. Symptoms can range from mild to severe, with the most severe form resulting in spontaneous bleeding into joints and muscles, leading to pain, swelling, and potential joint damage over time. Hemophilia A primarily affects males, as it is an X-linked recessive disorder, and is usually inherited from a carrier mother. However, about one third of cases result from a spontaneous mutation in the gene for factor VIII. Treatment typically involves replacement therapy with infusions of factor VIII concentrates to prevent or control bleeding episodes.

"Kringles" is not a term commonly used in medical literature. It is a term that originates from Scandinavian folklore, referring to a mythical figure who delivers gifts and sweets to children. However, in the context of biochemistry and cell biology, Kringle domains are structural motifs found in certain proteins.

Kringle domains are small, compact protein domains that contain approximately 80-100 amino acids, characterized by a distinctive pattern of disulfide bonds. These domains are named after the Danish pastry "kringle," which has a knot-like shape similar to the structure of these protein domains. Kringle domains are found in several proteins involved in blood coagulation, fibrinolysis, and inflammation, such as plasminogen, urokinase-type plasminogen activator (uPA), and tissue plasminogen activator (tPA). They play a role in protein-protein interactions, cell signaling, and protease activation.

Blood specimen collection is the process of obtaining a sample of blood from a patient for laboratory testing and analysis. This procedure is performed by trained healthcare professionals, such as nurses or phlebotomists, using sterile equipment to minimize the risk of infection and ensure accurate test results. The collected blood sample may be used to diagnose and monitor various medical conditions, assess overall health and organ function, and check for the presence of drugs, alcohol, or other substances. Proper handling, storage, and transportation of the specimen are crucial to maintain its integrity and prevent contamination.

Postoperative hemorrhage is a medical term that refers to bleeding that occurs after a surgical procedure. This condition can range from minor oozing to severe, life-threatening bleeding. Postoperative hemorrhage can occur soon after surgery or even several days later, as the surgical site begins to heal.

The causes of postoperative hemorrhage can vary, but some common factors include:

1. Inadequate hemostasis during surgery: This means that all bleeding was not properly controlled during the procedure, leading to bleeding after surgery.
2. Blood vessel injury: During surgery, blood vessels may be accidentally cut or damaged, causing bleeding after the procedure.
3. Coagulopathy: This is a condition in which the body has difficulty forming blood clots, increasing the risk of postoperative hemorrhage.
4. Use of anticoagulant medications: Medications that prevent blood clots can increase the risk of bleeding after surgery.
5. Infection: An infection at the surgical site can cause inflammation and bleeding.

Symptoms of postoperative hemorrhage may include swelling, pain, warmth, or discoloration around the surgical site, as well as signs of shock such as rapid heartbeat, low blood pressure, and confusion. Treatment for postoperative hemorrhage depends on the severity of the bleeding and may include medications to control bleeding, transfusions of blood products, or additional surgery to stop the bleeding.

Drug-Induced Liver Injury (DILI) is a medical term that refers to liver damage or injury caused by the use of medications or drugs. This condition can vary in severity, from mild abnormalities in liver function tests to severe liver failure, which may require a liver transplant.

The exact mechanism of DILI can differ depending on the drug involved, but it generally occurs when the liver metabolizes the drug into toxic compounds that damage liver cells. This can happen through various pathways, including direct toxicity to liver cells, immune-mediated reactions, or metabolic idiosyncrasies.

Symptoms of DILI may include jaundice (yellowing of the skin and eyes), fatigue, abdominal pain, nausea, vomiting, loss of appetite, and dark urine. In severe cases, it can lead to complications such as ascites, encephalopathy, and bleeding disorders.

The diagnosis of DILI is often challenging because it requires the exclusion of other potential causes of liver injury. Liver function tests, imaging studies, and sometimes liver biopsies may be necessary to confirm the diagnosis. Treatment typically involves discontinuing the offending drug and providing supportive care until the liver recovers. In some cases, medications that protect the liver or promote its healing may be used.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Hemostatic techniques refer to various methods used in medicine to stop bleeding or hemorrhage. The goal of these techniques is to promote the body's natural clotting process and prevent excessive blood loss. Some common hemostatic techniques include:

1. Mechanical compression: Applying pressure directly to the wound to physically compress blood vessels and stop the flow of blood. This can be done manually or with the use of medical devices such as clamps, tourniquets, or compression bandages.
2. Suturing or stapling: Closing a wound with stitches or staples to bring the edges of the wound together and allow the body's natural clotting process to occur.
3. Electrocautery: Using heat generated by an electrical current to seal off blood vessels and stop bleeding.
4. Hemostatic agents: Applying topical substances that promote clotting, such as fibrin glue, collagen, or gelatin sponges, to the wound site.
5. Vascular embolization: Inserting a catheter into a blood vessel and injecting a substance that blocks the flow of blood to a specific area, such as a bleeding tumor or aneurysm.
6. Surgical ligation: Tying off a bleeding blood vessel with suture material during surgery.
7. Arterial or venous repair: Repairing damaged blood vessels through surgical intervention to restore normal blood flow and prevent further bleeding.

Phospholipids are a major class of lipids that consist of a hydrophilic (water-attracting) head and two hydrophobic (water-repelling) tails. The head is composed of a phosphate group, which is often bound to an organic molecule such as choline, ethanolamine, serine or inositol. The tails are made up of two fatty acid chains.

Phospholipids are a key component of cell membranes and play a crucial role in maintaining the structural integrity and function of the cell. They form a lipid bilayer, with the hydrophilic heads facing outwards and the hydrophobic tails facing inwards, creating a barrier that separates the interior of the cell from the outside environment.

Phospholipids are also involved in various cellular processes such as signal transduction, intracellular trafficking, and protein function regulation. Additionally, they serve as emulsifiers in the digestive system, helping to break down fats in the diet.

Fibrinolytic agents are medications that dissolve or break down blood clots by activating plasminogen, which is converted into plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the structural protein in blood clots. Fibrinolytic agents are used medically to treat conditions such as acute ischemic stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction (heart attack) by restoring blood flow in occluded vessels. Examples of fibrinolytic agents include alteplase, reteplase, and tenecteplase. It is important to note that these medications carry a risk of bleeding complications and should be administered with caution.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Enzyme precursors are typically referred to as zymogens or proenzymes. These are inactive forms of enzymes that can be activated under specific conditions. When the need for the enzyme's function arises, the proenzyme is converted into its active form through a process called proteolysis, where it is cleaved by another enzyme. This mechanism helps control and regulate the activation of certain enzymes in the body, preventing unwanted or premature reactions. A well-known example of an enzyme precursor is trypsinogen, which is converted into its active form, trypsin, in the digestive system.

Blood platelets, also known as thrombocytes, are small, colorless cell fragments in our blood that play an essential role in normal blood clotting. They are formed in the bone marrow from large cells called megakaryocytes and circulate in the blood in an inactive state until they are needed to help stop bleeding. When a blood vessel is damaged, platelets become activated and change shape, releasing chemicals that attract more platelets to the site of injury. These activated platelets then stick together to form a plug, or clot, that seals the wound and prevents further blood loss. In addition to their role in clotting, platelets also help to promote healing by releasing growth factors that stimulate the growth of new tissue.

Acetaminophen is a medication used to relieve pain and reduce fever. It is a commonly used over-the-counter drug and is also available in prescription-strength formulations. Acetaminophen works by inhibiting the production of prostaglandins, chemicals in the body that cause inflammation and trigger pain signals.

Acetaminophen is available in many different forms, including tablets, capsules, liquids, and suppositories. It is often found in combination with other medications, such as cough and cold products, sleep aids, and opioid pain relievers.

While acetaminophen is generally considered safe when used as directed, it can cause serious liver damage or even death if taken in excessive amounts. It is important to follow the dosing instructions carefully and avoid taking more than the recommended dose, especially if you are also taking other medications that contain acetaminophen.

If you have any questions about using acetaminophen or are concerned about potential side effects, it is always best to consult with a healthcare professional.

Hirudin is not a medical term itself, but it is a specific substance with medical relevance. Hirudin is a naturally occurring anticoagulant that is found in the saliva of certain species of leeches (such as Hirudo medicinalis). This compound works by inhibiting the activity of thrombin, a key enzyme in the coagulation cascade, which ultimately results in preventing blood clot formation.

Medically, hirudin has been used in some research and therapeutic settings for its anticoagulant properties. For instance, recombinant hirudin (also known as lepirudin) is available for clinical use as an injectable anticoagulant to treat or prevent blood clots in specific medical conditions, such as heparin-induced thrombocytopenia (HIT).

In summary, Hirudins are a group of anticoagulant substances, primarily derived from leeches, that inhibit the activity of thrombin and have potential medical applications in preventing or treating blood clots.

The liver is a large, solid organ located in the upper right portion of the abdomen, beneath the diaphragm and above the stomach. It plays a vital role in several bodily functions, including:

1. Metabolism: The liver helps to metabolize carbohydrates, fats, and proteins from the food we eat into energy and nutrients that our bodies can use.
2. Detoxification: The liver detoxifies harmful substances in the body by breaking them down into less toxic forms or excreting them through bile.
3. Synthesis: The liver synthesizes important proteins, such as albumin and clotting factors, that are necessary for proper bodily function.
4. Storage: The liver stores glucose, vitamins, and minerals that can be released when the body needs them.
5. Bile production: The liver produces bile, a digestive juice that helps to break down fats in the small intestine.
6. Immune function: The liver plays a role in the immune system by filtering out bacteria and other harmful substances from the blood.

Overall, the liver is an essential organ that plays a critical role in maintaining overall health and well-being.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Phosphatidylserines are a type of phospholipids that are essential components of the cell membrane, particularly in the brain. They play a crucial role in maintaining the fluidity and permeability of the cell membrane, and are involved in various cellular processes such as signal transduction, protein anchorage, and apoptosis (programmed cell death). Phosphatidylserines contain a polar head group made up of serine amino acids and two non-polar fatty acid tails. They are abundant in the inner layer of the cell membrane but can be externalized to the outer layer during apoptosis, where they serve as signals for recognition and removal of dying cells by the immune system. Phosphatidylserines have been studied for their potential benefits in various medical conditions, including cognitive decline, Alzheimer's disease, and depression.

Surgical blood loss is the amount of blood that is lost during a surgical procedure. It can occur through various routes such as incisions, punctures or during the removal of organs or tissues. The amount of blood loss can vary widely depending on the type and complexity of the surgery being performed.

Surgical blood loss can be classified into three categories:

1. Insensible losses: These are small amounts of blood that are lost through the skin, respiratory tract, or gastrointestinal tract during surgery. They are not usually significant enough to cause any clinical effects.
2. Visible losses: These are larger amounts of blood that can be seen and measured directly during surgery. They may require transfusion or other interventions to prevent hypovolemia (low blood volume) and its complications.
3. Hidden losses: These are internal bleeding that cannot be easily seen or measured during surgery. They can occur in the abdominal cavity, retroperitoneal space, or other areas of the body. They may require further exploration or imaging studies to diagnose and manage.

Surgical blood loss can lead to several complications such as hypovolemia, anemia, coagulopathy (disorders of blood clotting), and organ dysfunction. Therefore, it is essential to monitor and manage surgical blood loss effectively to ensure optimal patient outcomes.

Reference standards in a medical context refer to the established and widely accepted norms or benchmarks used to compare, evaluate, or measure the performance, accuracy, or effectiveness of diagnostic tests, treatments, or procedures. These standards are often based on extensive research, clinical trials, and expert consensus, and they help ensure that healthcare practices meet certain quality and safety thresholds.

For example, in laboratory medicine, reference standards may consist of well-characterized samples with known concentrations of analytes (such as chemicals or biological markers) that are used to calibrate instruments and validate testing methods. In clinical practice, reference standards may take the form of evidence-based guidelines or best practices that define appropriate care for specific conditions or patient populations.

By adhering to these reference standards, healthcare professionals can help minimize variability in test results, reduce errors, improve diagnostic accuracy, and ensure that patients receive consistent, high-quality care.

"Quality control" is a term that is used in many industries, including healthcare and medicine, to describe the systematic process of ensuring that products or services meet certain standards and regulations. In the context of healthcare, quality control often refers to the measures taken to ensure that the care provided to patients is safe, effective, and consistent. This can include processes such as:

1. Implementing standardized protocols and guidelines for care
2. Training and educating staff to follow these protocols
3. Regularly monitoring and evaluating the outcomes of care
4. Making improvements to processes and systems based on data and feedback
5. Ensuring that equipment and supplies are maintained and functioning properly
6. Implementing systems for reporting and addressing safety concerns or errors.

The goal of quality control in healthcare is to provide high-quality, patient-centered care that meets the needs and expectations of patients, while also protecting their safety and well-being.

Hemostatics are substances or agents that promote bleeding cessation or prevent the spread of bleeding. They can act in various ways, such as by stimulating the body's natural clotting mechanisms, constricting blood vessels to reduce blood flow, or forming a physical barrier to block the bleeding site.

Hemostatics are often used in medical settings to manage wounds, injuries, and surgical procedures. They can be applied directly to the wound as a powder, paste, or gauze, or they can be administered systemically through intravenous injection. Examples of hemostatic agents include fibrin sealants, collagen-based products, thrombin, and oxidized regenerated cellulose.

It's important to note that while hemostatics can be effective in controlling bleeding, they should be used with caution and only under the guidance of a healthcare professional. Inappropriate use or overuse of hemostatic agents can lead to complications such as excessive clotting, thrombosis, or tissue damage.

Indicators and reagents are terms commonly used in the field of clinical chemistry and laboratory medicine. Here are their definitions:

1. Indicator: An indicator is a substance that changes its color or other physical properties in response to a chemical change, such as a change in pH, oxidation-reduction potential, or the presence of a particular ion or molecule. Indicators are often used in laboratory tests to monitor or signal the progress of a reaction or to indicate the end point of a titration. A familiar example is the use of phenolphthalein as a pH indicator in acid-base titrations, which turns pink in basic solutions and colorless in acidic solutions.

2. Reagent: A reagent is a substance that is added to a system (such as a sample or a reaction mixture) to bring about a chemical reaction, test for the presence or absence of a particular component, or measure the concentration of a specific analyte. Reagents are typically chemicals with well-defined and consistent properties, allowing them to be used reliably in analytical procedures. Examples of reagents include enzymes, antibodies, dyes, metal ions, and organic compounds. In laboratory settings, reagents are often prepared and standardized according to strict protocols to ensure their quality and performance in diagnostic tests and research applications.

Hepatectomy is a surgical procedure that involves the removal of part or all of the liver. This procedure can be performed for various reasons, such as removing cancerous or non-cancerous tumors, treating liver trauma, or donating a portion of the liver to another person in need of a transplant (live donor hepatectomy). The extent of the hepatectomy depends on the medical condition and overall health of the patient. It is a complex procedure that requires significant expertise and experience from the surgical team due to the liver's unique anatomy, blood supply, and regenerative capabilities.

Antifibrinolytic agents are a class of medications that inhibit the breakdown of blood clots. They work by blocking the action of enzymes called plasminogen activators, which convert plasminogen to plasmin, the main enzyme responsible for breaking down fibrin, a protein that forms the framework of a blood clot.

By preventing the conversion of plasminogen to plasmin, antifibrinolytic agents help to stabilize existing blood clots and prevent their premature dissolution. These medications are often used in clinical settings where excessive bleeding is a concern, such as during or after surgery, childbirth, or trauma.

Examples of antifibrinolytic agents include tranexamic acid, aminocaproic acid, and epsilon-aminocaproic acid. While these medications can be effective in reducing bleeding, they also carry the risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, due to their pro-coagulant effects. Therefore, they should be used with caution and only under the close supervision of a healthcare provider.

"Cattle" is a term used in the agricultural and veterinary fields to refer to domesticated animals of the genus *Bos*, primarily *Bos taurus* (European cattle) and *Bos indicus* (Zebu). These animals are often raised for meat, milk, leather, and labor. They are also known as bovines or cows (for females), bulls (intact males), and steers/bullocks (castrated males). However, in a strict medical definition, "cattle" does not apply to humans or other animals.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Viral hepatitis in humans refers to inflammation of the liver caused by infection with viruses that primarily target the liver. There are five main types of human viral hepatitis, designated as Hepatitis A, B, C, D, and E virus (HAV, HBV, HCV, HDV, and HEV). These viruses can cause a range of illnesses, from acute self-limiting hepatitis to chronic hepatitis, which can lead to cirrhosis and liver cancer.

1. Hepatitis A virus (HAV) is typically spread through the fecal-oral route, often through contaminated food or water. It usually results in an acute self-limiting infection, but rarely can cause chronic hepatitis in individuals with weakened immune systems.
2. Hepatitis B virus (HBV) is primarily transmitted through contact with infected blood, semen, and other bodily fluids. It can lead to both acute and chronic hepatitis, which may result in cirrhosis and liver cancer if left untreated.
3. Hepatitis C virus (HCV) is predominantly spread through exposure to infected blood, such as through sharing needles or receiving contaminated blood transfusions. Chronic hepatitis C is common, and it can lead to serious liver complications like cirrhosis and liver cancer if not treated.
4. Hepatitis D virus (HDV) is an incomplete virus that requires the presence of HBV for its replication. HDV infection occurs only in individuals already infected with HBV, leading to more severe liver disease compared to HBV monoinfection.
5. Hepatitis E virus (HEV) is primarily transmitted through the fecal-oral route, often through contaminated food or water. It usually results in an acute self-limiting infection but can cause chronic hepatitis in pregnant women and individuals with weakened immune systems.

Prevention measures include vaccination for HAV and HBV, safe sex practices, avoiding sharing needles, and ensuring proper hygiene and sanitation to prevent fecal-oral transmission.

Activated Protein C (APC) resistance is a condition in which the body's natural anticoagulant system is impaired, leading to an increased risk of thrombosis or blood clot formation. APC is an enzyme that plays a crucial role in regulating blood coagulation by inactivating clotting factors Va and VIIIa.

APC resistance is most commonly caused by a genetic mutation in the Factor V gene, known as Factor V Leiden. This mutation results in the production of a variant form of Factor V called Factor V Leiden, which is resistant to APC-mediated inactivation. As a result, the body's ability to regulate blood clotting is impaired, leading to an increased risk of thrombosis.

APC resistance can be measured by performing a functional assay that compares the activity of APC in normal plasma versus plasma from a patient with suspected APC resistance. The assay measures the rate of inactivation of Factor Va by APC, and a reduced rate of inactivation indicates APC resistance.

It is important to note that not all individuals with APC resistance will develop thrombosis, and other factors such as age, obesity, pregnancy, oral contraceptive use, and smoking can increase the risk of thrombosis in individuals with APC resistance.

Hydroxyethyl starch derivatives are modified starches that are used as plasma expanders in medicine. They are created by chemically treating corn, potato, or wheat starch with hydroxylethyl groups, which makes the starch more soluble and less likely to be broken down by enzymes in the body. This results in a large molecule that can remain in the bloodstream for an extended period, increasing intravascular volume and improving circulation.

These derivatives are available in different molecular weights and substitution patterns, which affect their pharmacokinetics and pharmacodynamics. They are used to treat or prevent hypovolemia (low blood volume) due to various causes such as bleeding, burns, or dehydration. Common brand names include Hetastarch, Pentastarch, and Voluven.

It's important to note that the use of hydroxyethyl starch derivatives has been associated with adverse effects, including kidney injury, coagulopathy, and pruritus (severe itching). Therefore, their use should be carefully monitored and restricted to specific clinical situations.

"Test ID: PT Prothrombin Time, Plasma". D'Angelo A, Galli L, Lang H (1997). "Comparison of mean normal prothrombin time (PT) ... The prothrombin time ratio is the ratio of a subject's measured prothrombin time (in seconds) to the normal laboratory ... Indeed, a new prothrombin time variant, the Fiix prothrombin time, intended solely for monitoring warfarin and other vitamin K ... PTnormal is established as the geometric mean of the prothrombin times (PT) of a reference sample group. The prothrombin time ...
Anticoagulants: Coadministration may prolong prothrombin time. Aspirin: Fenoprofen Cl may be increased; coadministration is not ...
Blood tests: Prothrombin time Partial thromboplastin time "hemostasis". Merriam-Webster Dictionary. Retrieved 2016-01-21. " ... Doctors of this time realized if these were plugged, blood could not continue to flow out of the body. Nevertheless, it took ... At this time many more advances in the general medical field were developed through the study of Egyptian mummification ... Putting pressure and/or dressing to a bleeding wound slows the process of blood loss, allowing for more time to get to an ...
Bleeding in an infant without vitamin K supplementation with elevated prothrombin time (PT) that is corrected by vitamin K ... administration which restores the prothrombin time rapidly. Severe bleeding may require blood products such as fresh frozen ... plasma (FFP), a prothrombin complex concentrate (PCC). Sutor, Anton; von Kries, Rüdiger; Cornelissen, Marlies; McNinch, Andrew ...
Prothrombin time increases, since the liver synthesizes clotting factors. Globulins increase due to shunting of bacterial ... Clotting function is estimated by lab values, mainly platelet count, prothrombin time (PT), and international normalized ratio ... Over time, scar tissue can replace normal functioning tissue, leading to the impaired liver function of cirrhosis. The disease ... Liver damage has also been attributed to heroin usage over an extended period of time as well. NASH has a number of causes, ...
Prolonged prothrombin and activated partial thromboplastin times are typical. Urinalysis can show bilirubinuria, proteinuria, ... RHD caused by RHDVa was reported for the first time in the United Kingdom in 1992. This initial epidemic was brought under ... Had the disease been introduced at a better time, control of the population would have been more effective, but it was released ... As consequence, thousands of rabbits have died or have been slaughtered each time. The virus is also believed to be thriving in ...
This can lead to an increase in prothrombin time. Zileuton is an active oral inhibitor of the enzyme 5-lipoxygenase, which ... although dsignificant increase in prothrombin time is not obvious. It is advised that the doses of each medication be monitored ... The recommended dose of Zyflo is one 600 mg tablet, four times per day. The tablets may be split in half to make them easier to ... Following oral administration zileuton is rapidly absorbed with a mean time to peak blood serum concentration of 1.7 hours and ...
... prothrombin time, partial thromboplastin time. Imaging tests such as transient elastography, ultrasound and magnetic resonance ... In liver disease, prothrombin time is longer than usual. In addition, the amounts of both coagulation factors and ... By the time accumulating epigenetic and mutational changes eventually cause hepatocellular carcinoma, epigenetic alterations ...
Meanwhile, prothrombin time is assessed to rule out coagulopathy. Informed consent regarding the risks of the procedure is ... Embolization (a minimally invasive surgical technique) over time has played an increasingly significant role in the multimodal ... over time these coils encourage formation of connective tissue at the site, strengthening the vessel walls. In some ... circulation time, and collateral flow. Extracranial diseases are: Subclavian steal syndrome, rupture of the carotid artery, ...
These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin, bilirubin (direct and ... Prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and INR are measures of the extrinsic pathway of ... "Prothrombin Time Test and INR (PT/INR): MedlinePlus Medical Test". medlineplus.gov. Retrieved 25 February 2021. Kingston, ... GGT can increase by 10 times in alcoholism. GGT can increase by 2 to 3 times in 50% of the patients with non-alcoholic liver ...
These same herbal supplements taken with warfarin increased prothrombin time. By containing significant content of vitamin K, ... When sitting for long periods of time, such as when traveling for more than four hours: Get up and walk around every 2 to 3 ... Dong quai, garlic, ginger, Ginkgo biloba, bilberry and feverfew can increase bleeding time. ...
Prolonged prothrombin time can be caused by vitamin K deficiency. Serological studies. Specific tests are carried out to ...
The risk of bleeding may be increased if: prothrombin time > 21 seconds international normalized ratio > 1.6 platelet count < ...
"Prothrombin Time (PT) w/INR and Partial Thromboplastin Time (PTT) Blood Test". Walk-In Lab. Retrieved 2018-09-17. "Hemorrhagic ... Prothrombin time and partial thromboplastin time blood tests are useful to investigate the reason behind the excessive bleeding ... Blood transfusion involves the transfer of plasma containing all the necessary coagulating factors (fibrinogen, prothrombin, ...
The prothrombin time (PT) and partial thromboplastin time (PTT) is often prolonged. Subclinical horses may only show elevated ... Decreases in the SDH and prothrombin time along with improvement in appetite are the best positive predictive indicators of ...
It may increase the INR and prothrombin times in people on warfarin. Fluorouracil's efficacy is decreased when used alongside ...
It has developed a MEMs based microviscometer for the prothrombin time test. In 2006 the company expanded its premises and ...
Tinzaparin does not affect the international normalized ratio (INR), prothrombin time (PT).[citation needed] Anti-factor Xa ...
As a result, TBA prolongs the prothrombin time when interacting with prothrombin. TBA entered the phase I clinical trial for ... In addition, the TBA-HD22 avidity can be examined by ecarin clotting time. Ecarin activates prothrombin and accordingly ... shows significant improvement both in the assay of activated partial thromboplastin time, clotting time and thrombin-induced ... As a result, TBA-HD22 construct cannot improve the ecarin clotting time, which further demonstrates the improvement of aptamer ...
Prolongation of prothrombin time in coagulation testing is associated with severe bleeding manifestation. However, low platelet ... but are time-consuming. Therefore, total genomic sequencing could potentially replace these two methods as the new gold ...
... does not usually affect prothrombin time, partial thromboplastin time or platelet counts; it does not inhibit ... Thomas K (24 June 2012). "In Documents on Pain Drug, Signs of Doubt and Deception". The New York Times. Archived from the ... Berenson A (29 April 2006). "Celebrex Ads Are Back, Dire Warnings and All". The New York Times. Archived from the original on 7 ... Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI ...
Prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen tests should be performed. Platelet ... At times, patients with Waldenström macroglobulinemia may exhibit more than one M protein. Plasma viscosity must be measured. ... For a time, Waldenström macroglobulinemia was considered to be related to multiple myeloma because of the presence of ... Older diagnosis and treatments resulted in published reports of median survival of approximately 5 years from time of diagnosis ...
CBC Prothrombin time Fingersticks are routine for hardy[citation needed] adults, but are generally performed on children and ... Whole Blood Prothrombin Time". Arch Intern Med. 149 (11): 2509-11. doi:10.1001/archinte.1989.00390110085018. PMID 2818110. ...
While at the hospital, he developed the prothrombin time test (also known as the Quick test), which is used in the regulation ... He also developed the prothrombin consumption time test, which became useful in diagnosing haemophilia. He later moved to ... having developed the original prothrombin time test. Quick was born in Theresa, Wisconsin in 1894, the son of a hardware ... The New York Times. Retrieved April 30, 2021. "Individual Reactions to Some Drugs Analogous to Hay Fever". The Science News- ...
Rejection may present with lab findings: elevated AST, ALT, GGT; abnormal liver function values such as prothrombin time, ... The risk of ischemic cholangiopathy increases with longer durations of cold ischemia time, which is the time that the organ ... time period of abstinence is variable) improvement in heart function, e.g. by percutaneous coronary intervention or bypass ... of the allograft may happen at any time. ...
The genetic variant prothrombin G20210A, which increases prothrombin levels, increases risk by about 2.5 times. Additionally, ... An INR is determined from the ratio of a patient's prothrombin time (PT) to a standardized control PT. A normal INR for those ... of the time, and a central venous catheter or transvenous pacemaker about 9% of the time. During pregnancy and after childbirth ... At times, DVT can cause symptoms in both arms or both legs, as with bilateral DVT. Rarely, a clot in the inferior vena cava can ...
... clotting assays such as prothrombin time and aPTT will be highly disturbed. Spontaneous recovery from coagulopathy is seen 14 ... The test is considered to be a replacement for thrombin time, and is used when heparin is present in the sample. The enzyme is ... Generally nocturnal, it may forage at any time of the day, though, if necessary. These snakes are also easily agitated. The ...
Typical are normal thrombin time, prolonged prothrombin time (PT) and prolonged partial thromboplastin time(PTT). FX antigen ... A specific FX concentrate was not available as of 2009[update]. Prothrombin complex concentrate (PCC) supplies FX with a risk ... Veneri D, Giuffrida AC, Bonalumi A, Calabria S, Gandini G, Ambrosetti A, Minuz P (November 2016). "Use of prothrombin complex ... Produced in the liver FX when activated cleaves prothrombin to generate thrombin in the intrinsic pathway of coagulation. This ...
Other primary lab tests for liver function include gamma glutamyl transpeptidase (GGT) and prothrombin time (PT). No single ... Levels 5-10 times tend to indicate viral hepatitis. Levels less than 5 times normal tend to indicate drug toxicity. Acute ... Both of these conditions can also have ALT and AST greater than 20 times normal. GGT levels greater than 10 times normal ... ALP levels greater than 5 times normal tend to indicate obstruction, while levels greater than 10 times normal can indicate ...
Bleeding time, activated partial thromboplastin time, prothrombin time, and euglobulin lysis time were within normal limits. ...
"Test ID: PT Prothrombin Time, Plasma". DAngelo A, Galli L, Lang H (1997). "Comparison of mean normal prothrombin time (PT) ... The prothrombin time ratio is the ratio of a subjects measured prothrombin time (in seconds) to the normal laboratory ... Indeed, a new prothrombin time variant, the Fiix prothrombin time, intended solely for monitoring warfarin and other vitamin K ... PTnormal is established as the geometric mean of the prothrombin times (PT) of a reference sample group. The prothrombin time ...
... is a blood test that measures the time it takes for the liquid portion (plasma) of your blood to clot. It measures the function ... is a blood test that measures the time it takes for the liquid portion (plasma) of your blood to clot. It measures the function ... PT; Pro-time; Anticoagulant-prothrombin time; Clotting time: protime; INR; International normalized ratio ... Prothrombin time (PT) is a blood test that measures the time it takes for the liquid portion (plasma) of your blood to clot. It ...
What Is a Prothrombin Time Test?. A prothrombin time (PT) test measures how long it takes for a clot to form in a blood sample ... Blood Test: Prothrombin Time (PT). What Is a Blood Test?. By taking and testing a small sample of a persons blood, doctors can ...
Over time, his prothrombin time (PT)4 international normalized ratio (INR) values were stable and checked regularly at an ... myADLM.org // ... // Clinical Chemistry Journal // Clinical Case Studies // Prolonged Prothrombin Time After Discontinuing ... Prolonged Prothrombin Time After Discontinuing Vitamin K Antagonist. *Undetectable HDL Cholesterol In A Patient With FluLike ... You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy ...
A modification is described which reduces considerably the amount of pipetting involved in the estimation of "prothrombin time ... A SIMPLIFICATION IN THE ESTIMATION OF "PROTHROMBIN TIME" FOR THE CONTROL OF ANTICOAGULANT THERAPY ... A SIMPLIFICATION IN THE ESTIMATION OF "PROTHROMBIN TIME" FOR THE CONTROL OF ANTICOAGULANT THERAPY ...
Tested for antithrombotic potency after intravenous administration of 3 mg/kg to prolong prothrombin time(PT), activity ...
Prolonged Prothrombin Time and Partial Thromboplastin Time in Disseminated Intravascular Coagulation not Due to Deficiency of ... Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for ... RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis‐induced coagulopathy than fibrin‐related ... Agreements Between the Prothrombin Times of Blood Treated In Vitro with Heparinase During Cardiopulmonary Bypass (CPB) and ...
A Prothrombin time test is a test used to detect and diagnose bleeding disorder or clotting disorder in the body.,/p, ... Activated Partial Prothrombin Time Test Overview. A Prothrombin time test is a test used to detect and diagnose bleeding ... The price of Prothrombin Time (PT) in Ahmednagar is ₹ 325. We are committed to deliver accurate and quality results from the ... Summary Price Of Prothrombin Time (PT) in Ahmednagar. Metropolis Healthcare is a leading diagnostics centre and pathology lab ...
The prothrombin time is the time it takes plasma to clot after addition of tissue factor (obtained from animals). This measures ... Has the time arrived to replace the quick prothrombin time test for monitoring oral anticoagulant therapy? Clin Chem 2005;51: ... Synonyms and keywords: International normalized ratio, INR, prothrombin ratio, PR, PT Overview. The prothrombin time (PT) and ... The prothrombin ratio is the prothrombin time for a patient, divided by the result for control plasma. ...
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. ... This means that every time you visit this website you will need to enable or disable cookies again. ...
blood test diagnostics health checkup fever panel PROTHROMBIN TIME WITH INR book a free test diabetese hb1ac ...
Details of Prothrombin Time ( PT ) What is Prothrombin Time-PT?. Prothrombin time (PT) is a blood test that measures the time ... Details of Prothrombin Time ( PT ) What is Prothrombin Time-PT?. Prothrombin time (PT) is a blood test that measures the time ... clotting time, diagnostics, partial thromboplastin time, prothrombin time ... Prothrombin Time vs Partial Thromboplastin Time. ... Prothrombin Time (PT) with INR - Health One Labs. Prothrombin Time (PT) with INR quantity. Add to cart. SKU: Prothrombin-Time ...
This test measures how long it takes your blood to clot. Its used to monitor the effects of the medication warfarin, and can help identify possible hereditary and clotting disorders. This test does not require fasting.
The prothrombin time is a measure of the integrity of the extrinsic and final common pathways of the coagulation cascade. ... A basic understanding of the coagulation pathway is required to interpret prothrombin time result (see the image below). ... encoded search term (Prothrombin Time) and Prothrombin Time What to Read Next on Medscape ... How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. ...
The prothrombin time is a measure of the integrity of the extrinsic and final common pathways of the coagulation cascade. ... A basic understanding of the coagulation pathway is required to interpret prothrombin time result (see the image below). ... encoded search term (Prothrombin Time) and Prothrombin Time What to Read Next on Medscape ... How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. ...
Prothrombin time (PT) is a measurement of the amount of time needed for a clot to form after the addition of thromboplastin and ... The prothrombin time (PT) blood test is used to screen for initial coagulation disorders. ... What does the prothrombin time mean?. Prothrombin time (PT) is a measurement of the amount of time needed for a clot to form ... What is the prothrombin time blood test used for?. The prothrombin time (PT) test is one of the most important screening tests ...
Home / All Tests / Prothrombin Time (Pt With INR). All Tests. Prothrombin Time (Pt With INR). ₨ 750. ...
Drugs that prolong the prothrombin time. Note that the S-isomer is more potent than the R-isomer; thus, drugs that inhibit S- ... The anticoagulant effect is best quantified by baseline and daily repeated measurement of the prothrombin time (PT) and the ... Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?. Pediatrics. 2000 Feb. 105(2):402-4. [ ... If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel ...
Prothrombin Time (PT) - Assess Your Bleeding Disorders…. Diposkan pada 24/08/2021. 24/08/2021. oleh PT Multimedilab ... A prothrombin time (PT) is a blood test used to help identify & diagnose bleeding disorders or clotting disorders in your ... Prothrombin is a protein made by the liver. It is one of the clotting (coagulation) factors. When you have a cut or injury, ... Clotting time is abnormally increased due to the absence or abnormality of clotting factors. Normally, APTT is also checked ...
The prothrombin time (PT) is a kinetic screening test performed by adding a sensitive tissue thromboplastin reagent and calcium ... To prepare plasma, centrifuge blue top tubes at 1500g for 15 minutes and remove the plasma and centrifuge a second time at ... The PT assesses the extrinsic pathway of coagulation that includes factors VII, X, prothrombin, and fibrinogen. Prolongation of ...
Parameters of both coagulation (prothrombin time) and platelet function (bleeding time and the alpha and ma parameters of ... Haemostasis was evaluated by clotting assays, bleeding time and thromboelastography 10 min before and 10 min and 1, 2, 4, 8 and ... Parameters of both coagulation (prothrombin time) and platelet function (bleeding time and the alpha and ma parameters of ... Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of ...
... s list of labs providing Prothrombin Time Test services in Kolkata & book Prothrombin Time Test home Collection now! ... Want to book affordable Prothrombin Time Test online? Check out Flebo.in ... Prothrombin Time Test In Delhi. () Starts from 175* The prothrombin time or pt inr test in Delhi is conducted to check the time ... About Prothrombin Time Test. Why is the Prothrombin Time Test done? When a person gets a cut, they bleed for a while before ...
... prothrombin time ≥ 40%; serum bilirubin ≤ 1.5 × ULN and serum transaminases ≤ 5 × ULN. Patients were excluded if they had ... At the time of analysis, 67 patients (81%) had died, 32 (73%) in the sorafenib arm and 35 (90%) in the sorafenib plus GEMOX arm ... 2). The median time to progression was 4.6 months (95% CI: 3.8-6.2) and 6.2 (95% CI: 3.7-7.2) in the sorafenib alone vs. ... PFS was defined as the time between the beginning of treatment to the first progression or death in case of progression ( ...
5.11 Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time 5.12 Development of Drug-Resistant Bacteria 6 ... Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time [see Warnings and Precautions (5.11) and Drug ... 5.11 Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time. Clinically relevant plasma concentrations of ... prothrombin time prolonged. Metabolism and Nutrition Disorders: appetite decreased NOS Musculoskeletal and Connective Tissue ...
The recommended retrieval time is in the first 12 days, but various authors have prolonged the time to retrieval with or ... If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel ... In 2002, this filter was approved by the FDA for retrieval times of up to 23 days. The introducer system has a profile similar ... 77] The average indwell time was 117 days (range, 24-426d). On abdominal CT scan in 40 of the 96 patients, 12 (30%) showed ...
The doctor may use a coagulation test called the prothrombin time or PT test. They take a small blood sample and then add ... Prothrombin time (PT). (2019).. https://www.ucsfhealth.org/medical-tests/003652. *. Schwalfenberg, G. K. (2017). Vitamins K1 ...
Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first ... You can at any time change or withdraw your consent from the Cookie Declaration on our website. Learn more about who we are, ...
Prothrombin time, %. 100 (99-100). 53 (58.9). 100 (100-100). 7 (70). 0.61. ... ALT, alanine aminotransferase; aPPT, activated partial thromboplastin time; AST, aspartate aminotransferase; ICU, intensive ...
Prothrombin time. This test measures the clotting time of plasma.. More Information. *Gilbert syndrome ... Some common tests that might be done at the same time as bilirubin testing include:. *Liver function tests. Blood tests that ... You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. ...
Both patients subsequently received 12 g of IVC delivered intravenously over 30 min, given 2 times daily for 7 days. Serial ... and prothrombin time. SARS-CoV-2 tests were negative at the end of the IVC treatment. A follow-up chest X-ray 4 days after the ... and prothrombin time, which remained mildly elevated (Table 2). The patient was released from COVID-19 ICU on Hospital Day 18 ... At the time of the visit, the patient was undergoing chemotherapy (oral Imatinib 600 mg daily) for chronic myelogenous leukemia ...
  • The prothrombin time (PT) - along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) - is an assay for evaluating the extrinsic pathway and common pathway of coagulation. (wikipedia.org)
  • PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X (Stuart-Prower factor). (wikipedia.org)
  • PT is often used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway and common pathway of coagulation. (wikipedia.org)
  • The prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) are measures of the extrinsic pathway of coagulation . (wikidoc.org)
  • It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. (lookformedical.com)
  • Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. (lookformedical.com)
  • A basic understanding of the coagulation pathway is required to interpret prothrombin time result (see the image below). (medscape.com)
  • The prothrombin time is a measure of the integrity of the extrinsic and final common pathways of the coagulation cascade. (medscape.com)
  • Bleeding time depends on various factors such as functions of platelets, endothelial cells of arteries, pathways of coagulation. (multimedilab.com)
  • The PT assesses the extrinsic pathway of coagulation that includes factors VII, X, prothrombin, and fibrinogen. (bloodworksnw.org)
  • The doctor may use a coagulation test called the prothrombin time or PT test. (medicalnewstoday.com)
  • Activated partial thromboplastin time (aPTT) and prothrombin time (PT) are clinical tests commonly used to screen for coagulation-factor deficiencies. (hw.ac.uk)
  • By measuring the amount of time the body takes to form a blood clot in a test tube, the aPTT test can determine the amount and the function of certain coagulation factors. (anylabtestnow.com)
  • The Activated Partial Thromboplastin Time (aPTT) measures the body's Ability To Form Blood Clots appropriately. (anylabtestnow.com)
  • Clotting is caused by a series of clotting factors which activate one another, including the conversion of prothrombin to thrombin. (metropolisindia.com)
  • It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors. (lookformedical.com)
  • It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. (lookformedical.com)
  • Clotting time of PLASMA mixed with a THROMBIN solution. (lookformedical.com)
  • The reference range for prothrombin time depends on the analytical method used, but is usually around 12-13 seconds (results should always be interpreted using the reference range from the laboratory that performed the test), and the INR in absence of anticoagulation therapy is 0.8-1.2. (wikipedia.org)
  • The INR was introduced in the early 1980s when it turned out that there was a large degree of variation between the various prothrombin time assays, a discrepancy mainly due to problems with the purity of the thromboplastin (tissue factor) concentrate. (wikidoc.org)
  • Haemostasis was evaluated by clotting assays, bleeding time and thromboelastography 10 min before and 10 min and 1, 2, 4, 8 and 24 h after factor VII infusion. (ox.ac.uk)
  • The MRX PT DOAC test is based on two simultaneously run prothrombin time (PT) assays, one DOAC-insensitive PT assay and one DOAC-sensitive PT assay. (isth.org)
  • Abnormal assays for factors II and VII in patients with unexplained bleeding and a normal PT, partial thromboplastin time, or INR, as determined by hospital or commercial laboratory tests. (cdc.gov)
  • Finally, in order to activate the extrinsic / tissue factor clotting cascade pathway, tissue factor (also known as factor III) is added and the time the sample takes to clot is measured optically. (wikipedia.org)
  • A related blood test is partial thromboplastin time (PTT) , which measures the function of a different part of the clotting system. (medlineplus.gov)
  • A Prothrombin time test is a test used to detect and diagnose bleeding disorder or clotting disorder in the body. (metropolisindia.com)
  • Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. (lookformedical.com)
  • An adult sample tube with a volume of 5 mL must be filled completely or to at least 60-80% of its volume, as an incompletely filled tube may result in a falsely prolonged clotting time. (medscape.com)
  • A prothrombin time (PT) is a blood test used to help identify & diagnose bleeding disorders or clotting disorders in your circulatory system. (multimedilab.com)
  • Higher values than reference means it takes blood longer time than usual, to for clot & lower values indicate quicker blood clotting than normal. (multimedilab.com)
  • Clotting time is abnormally increased due to the absence or abnormality of clotting factors. (multimedilab.com)
  • Rapid loss of protein C temporarily shifts the balance in favor of clotting until sufficient time has passed for warfarin to decrease the activity of coagulant factors. (medscape.com)
  • Prothrombin or factor II is essential for clotting. (flebo.in)
  • It is this factor that determines how soon or how delayed the clotting time is. (flebo.in)
  • This test measures the clotting time of plasma. (mayoclinic.org)
  • Compared with nonsedated cats, cats that required sedation had a significantly shorter clotting time and greater α angle, whereas reaction time and maximum amplitude were not significantly different. (avma.org)
  • Prothrombin is a protein produced by the liver. (metropolisindia.com)
  • Prothrombin is a protein made by the liver. (multimedilab.com)
  • Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. (ox.ac.uk)
  • The prothrombin gene and its liver-specific expression. (medscape.com)
  • Alkaline phosphatase, γ-glutamyl transpeptidase, and prothrombin time were independent predictors for significant liver inflammation and selected to establish the AGP-nomogram. (bvsalud.org)
  • For the prothrombin time test the appropriate sample is the blue top tube, or citrate tube, which is a liquid anticoagulant. (wikidoc.org)
  • The anticoagulant effect is best quantified by baseline and daily repeated measurement of the prothrombin time (PT) and the International Normalized Ratio (INR), which may not be elevated until 1-2 days postingestion. (medscape.com)
  • A clinically compatible case in which a high index of suspicion (credible threat or patient history regarding location and time) exists for a long-acting anticoagulant exposure, or an epidemiologic link exists between this case and a laboratory-confirmed case. (cdc.gov)
  • The test is performed by adding calcium and thromboplastin, an activator of the extrinsic pathway, to the blood sample then measuring the time (in seconds) required for fibrin clot formation. (medscape.com)
  • Critically ill dogs had significantly increased maximum amplitude, α angle, and global clot strength and significantly decreased clot formation time. (avma.org)
  • Deficiency of prothrombin leads to hypoprothrombinemia. (lookformedical.com)
  • In general, the prothrombin time is more sensitive to factor VII deficiency than factor deficiencies within the final common pathway. (medscape.com)
  • Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. (medscape.com)
  • Harel R, Shani D, Donohoe K. A case of congenital prothrombin deficiency and idiopathic thrombocytopenic purpura in a pregnant female. (medscape.com)
  • The prothrombin time was discovered by Dr Armand Quick and colleagues in 1935, [1] and a second method was published by Dr Paul Owren [2] (also called the "p and p" or "prothrombin and proconvertin" method). (wikidoc.org)
  • Factor VII has a short half-life and the carboxylation of its glutamate residues requires vitamin K. The prothrombin time can be prolonged as a result of deficiencies in vitamin K, warfarin therapy, malabsorption, or lack of intestinal colonization by bacteria (such as in newborns). (wikipedia.org)
  • The prothrombin time test also monitors the effects of the medicine warfarin. (flebo.in)
  • Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. (medscape.com)
  • Congenital deficiencies and abnormalities of prothrombin. (medscape.com)
  • The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). (lookformedical.com)
  • The blood is mixed, then centrifuged to separate blood cells from plasma (as prothrombin time is most commonly measured using blood plasma). (wikipedia.org)
  • Prothrombin time (PT) is a blood test that measures the time it takes for the liquid portion (plasma) of your blood to clot. (medlineplus.gov)
  • The prothrombin time can be measured roughly on whole blood (which is done in neonates ), but is more commonly measured from blood plasma . (wikidoc.org)
  • Absence or reduced levels of PROTHROMBIN in the blood. (lookformedical.com)
  • Your gift of blood, time or money saves lives. (bloodworksnw.org)
  • The INR or international normalized ratio provides an estimated time that a normal blood plasma sample will take to form the clot. (flebo.in)
  • This is done by collecting the plasma from the blood and subjecting it to some tissue factor and then recording the time taken for the clot to form. (flebo.in)
  • The prothrombin time test requires blood samples for the checking procedure. (flebo.in)
  • This dilution will cause a falsely long prothrombin time. (wikidoc.org)
  • The prothrombin time ratio is the ratio of a subject's measured prothrombin time (in seconds) to the normal laboratory reference PT. (wikipedia.org)
  • The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used. (wikipedia.org)
  • Most of the time, results are also given as what is called INR (international normalized ratio). (medlineplus.gov)
  • The prothrombin ratio is the prothrombin time for a patient, divided by the result for control plasma. (wikidoc.org)
  • This difference is expressed as a clot time ratio (CTR). (isth.org)
  • Prolonged prothrombin time (PT) and international normalized ratio (INR) (24 to 72 hours after exposure) persisting for weeks to months, as determined by hospital laboratory tests. (cdc.gov)
  • A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. (medscape.com)
  • Atasay B, Arsan S, Gunlemez A, Kemahli S, Akar N. Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center. (medscape.com)
  • Prevalence of factor V Leiden and prothrombin G20210A gene mutation. (medscape.com)
  • The prothrombin time is the time it takes plasma to clot after addition of tissue factor (obtained from animals such as rabbits, or recombinant tissue factor, or from brains of autopsy patients). (wikipedia.org)
  • Tissue factor (also known as factor III or thromboplastin ) is added, and the time the sample takes to clot is measured optically. (wikidoc.org)
  • The prothrombin time has significant interlaboratory variability influenced by the instrument, and more importantly, the reagent used. (medscape.com)
  • Congenital dysprothrombinemia: an inherited structural disorder of human prothrombin. (medscape.com)
  • Active, serious hemorrhage should be treated with four-factor prothrombin complex concentrate (PCC), if available. (medscape.com)
  • Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. (medscape.com)
  • 3 An up-to-date list of WHO International Standards and Reference Reagents is available at http://www.who.int/bloodproducts/catalogue/en/ (accessed 28 February 2013). (who.int)
  • We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. (metropolisindia.com)
  • In Part Four, turnaround time in a new centralized laboratory is improved. (isixsigma.com)
  • After successfully improving the processes in laboratory of Center A, the chain of medical dianostic clinics wanted to move forward with improving the turnaround time (TAT) in the newly established centralized laboratory servicing the 62 individual lab centers. (isixsigma.com)
  • INR = ( PT test PT normal ) ISI {\displaystyle {\text{INR}}=\left({\frac {{\text{PT}}_{\text{test}}}{{\text{PT}}_{\text{normal}}}}\right)^{\text{ISI}}} PTnormal is established as the geometric mean of the prothrombin times (PT) of a reference sample group. (wikipedia.org)
  • One of the key components to the interpretation of prothrombin time is a properly collected sample. (medscape.com)
  • Upon collection, the sample should be mixed gently by inversion 3 or 4 times and be tested within 2 hours if kept at room temperature (22-24ºC) or within 4 hours if kept cold (2-4ºC). (medscape.com)
  • Sample physicians were screened at the time of the survey to assure that they met the above-mentioned criteria, 794 physicians did not meet all of the criteria and were, therefore, ruled out of scope (ineligible) for the study. (cdc.gov)
  • Tested for antithrombotic potency after intravenous administration of 3 mg/kg to prolong prothrombin time(PT), activity expressed as PT inhibitor/PT control. (nih.gov)
  • The test measures the time that prothrombin takes to form a clot. (flebo.in)
  • The prothrombin time (PT) is a kinetic screening test performed by adding a sensitive tissue thromboplastin reagent and calcium chloride to plasma using an automated method. (bloodworksnw.org)
  • To prepare plasma, centrifuge blue top tubes at 1500g for 15 minutes and remove the plasma and centrifuge a second time at 1500g for an additional 15 minutes. (bloodworksnw.org)
  • Another metric was also introduced - the percentage of reports completed/returned to patients in a 24-hour period of time. (isixsigma.com)
  • Prothrombin time is typically analyzed by a laboratory technologist on an automated instrument at 37 °C (as a nominal approximation of normal human body temperature). (wikipedia.org)
  • The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed. (wikipedia.org)
  • The reference range for prothrombin time is 9.5-13.5 seconds. (medscape.com)
  • The time taken for the clot to form is between 10 to 13 seconds. (flebo.in)
  • This is the normal time, in seconds. (flebo.in)
  • In terms of INR, 1.1 or below is considered normal, and the prothrombin functioning is healthy. (flebo.in)
  • The prothrombin time or pt inr test in Delhi is conducted to check the time that prothrombin takes in order to form a clot. (flebo.in)
  • They live in a high-rise apartment building where the patient has been a handyman and part-time building manager for the past year. (cdc.gov)
  • The spectrum varies greatly, and symptoms overlap in time and duration. (medscape.com)
  • Severity of illness scores and platelet activation measurements were compared with survival time and duration and cost of hospitalization. (avma.org)